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CHAPTER – 1 
INTRODUCTION 
 Nanotechnology can be defined as the science and engineering involved in 
the design, synthesis, characterization and application of materials and devices 
whose smallest functional organization in at least one dimension is on the nanometer 
scale. 
One nanometer (nm) is equal to one-billionth of a meter, or about the width 
of 6 carbon atoms or 10 water molecules.                 (Sahoo S. K et al, 2007) 
 
Figure 1 
Nanotechnology in drug delivery and its significance 
 In pharmaceutical industries, nanotechnology can address issues such as 
extending product life, or can add to their performance and acceptability, either by 
increasing efficacy or improving safety and patient compliance. 
 Drug loading onto nanoparticles modifies cell and tissue distribution and 
leads to a more selective delivery of biologically active compounds to improve drug 
efficacy and reduces drug toxicity. 
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 Nanotechnology offers a solution for using the numerous chemical entities 
for treating brain disorders that are not clinically useful, because of the presence of 
the blood-brain barrier. 
 The increased vascular permeability coupled with an impaired lymphatic 
drainage in tumors allows an enhanced permeability and retention effect of the 
nanosystems in the tumors or inflamed tissues. 
The tendency of nanosystems to specifically localize in the reticulo-endothelial 
system (RES) also presents an excellent opportunity for passive targeting of drugs to 
the macrophages present in the liver and spleen.           
           (Sanjeeb k. Sahoo et al, 2003) 
 
Figure 2 
NANOANTIBIOTICS 
 Nanomaterials, which either show antimicrobial activity by themselves or 
elevate the effectiveness and safety of antibiotics administration, are called 
“nanoantibiotics”. 
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Antimicrobial nanoparticles (NPs) tackle multiple biological pathways found 
in broad species of microbes and many concurrent mutations would have to occur in 
order to develop resistance against NPs' antimicrobial activities. Unlike many 
antimicrobial agents currently being used, antimicrobial NPs may not pose direct and 
acute adverse effects, although there is potential toxicity upon long-term exposure. 
 
Figure 3 
Preparation of antimicrobial NPs could be cost-effective, compared with 
antibiotics synthesis, and they are quite stable enough for long-term storage with a 
prolonged shelf-life. In addition, some NPs can withstand harsh conditions, such as 
high temperature sterilization, under which conventional antibiotics are inactivated. 
                  (Young Jik Kwon et al, 2011) 
Advantages of Nanoantibiotics 
 Antibiotics delivery using nano materials offer multiple advantages, 
♦ Overcoming resistance 
♦ Improved solubility 
♦ Sustained and controlled release 
♦ Improved patient-compliance 
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♦ Minimized side effects 
♦ Enhanced cellular internalization 
♦ Controllable and relatively uniform distribution in the target tissue. 
Antimicrobial Nanometals 
Antibacterial nanometals consist of metals and metal oxides, naturally occurring 
antibacterial substances, carbon-based nanomaterials, and surfactant-based nano-
emulsions. High surface area to volume ratios and unique chemico-physical 
properties of various nanomaterials are believed to contribute to effective 
antimicrobial activities. 
Antimicrobial mechanisms of nanomaterials include, 
♦ Photocatalytic production of reactive oxygen species (ROS) that damage 
cellular and viral components 
♦ Compromising the bacterial cell wall/membrane 
♦ Interruption of energy transduction 
♦ Inhibition of enzyme activity and DNA synthesis 
 
Figure 4 
Some of the various types of antimicrobial nanometals being used are, 
♦ Silver Nanoparticles (Ag NPs) 
♦ Zinc oxide Nanoparticles (ZnO NPs) 
CHAPTER – 1                                                                                  INTRODUCTION 
MUCOADHESIVE TABLETS OF SLN LOADED WITH DRUG Page 5 
 
♦ Titanium dioxide Nanoparticles (TiO2 NPs) 
♦ Gold Nanoparticles (Au NPs) 
♦ Aluminium and Copper Nanoparticles (Al & Cu NPs) 
♦ Nitric oxide (NO) releasing Nanoparticles 
♦ Carbon Nanotubes (CNTs) 
        (Jagat R Kanwar et al, 2010) 
Nanoparticle carriers 
 Novel nanomaterials, NPs in particular have improved solubility of poorly 
water-soluble drugs, prolonged drug half-life and systemic circulation time, and 
sustained and stimuli-responsive drug release, which eventually lowers 
administration frequency and dose. Moreover, minimized systemic side effects via 
targeted delivery of antimicrobial drugs as well as combined, synergistic, and 
resistance-overcoming effects via co-delivery of multiple antimicrobial drugs can be 
achieved using NP carriers. 
Some of the nanocarriers used are, 
♦ Liposomes 
♦ Polymeric nanoparticles (NPs) 
♦ Solid Lipid Nanoparticles (SLNs) 
♦ Dendrimers 
 The use of nanotechnology in immunization, design and delivery of 
antimicrobial drugs, and diagnosis and control of cross-infections, particularly in 
overcoming antibiotics-resistant pathogens, serve as a promising alternative to the 
current antibiotics-based approaches.       
     (Young Jik Kwon et al) 
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SOLID LIPID NANOPARTICLES 
 Solid lipid nanoparticles (SLNs) are first introduced in 1991, which are the 
forefront of rapidly developing field of nanotechnology with several potential 
applications in drug delivery and research. SLNs are sub micron colloidal carrier 
ranging from 50-1000nm, which are composed of physiological lipid disperse in 
water or aquoeus surfactant solutions.  
 
Figure 5 
SLNs posses a solid lipid core matrix that can solubilise lipophilic molecules 
and the lipid core is stabilized by surfactants.  The successful implementation of 
nanoparticles for drug delivery depends on their ability to penetrate through several 
anatomical barriers, sustained release of their contents and the stability in nanometer 
size.  Many biocompatible or biodegradable lipids, which are solid at room 
temperature can be obtained in high purity are generally recognized as safe (GRAS) 
and are inexpensive. Some of commonly used solid lipids include triglycerides, 
carnauba wax, beeswax, cetyl alcohol, emulsifying wax, cholesterol and cholestryl 
butyrate. Nano- and micro-particles made of these lipids and suspended in water 
offer an option for formulating both BCS Class II and IV drugs as well as biologics 
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that may overcome the issues of shelf life stability, cost and toxicity associated with 
the use of organic solvents.           (Abdul Hasan Sathali A et al, 2012) 
Advantages of SLNs 
♦ Smaller size and relative narrow size distribution 
♦ Controlled and sustained release of active drug 
♦ The incorporated drug is protected from onslaughts of biochemical 
degradation. 
♦ Can be lyophilized 
♦ Relatively cheap and stable 
♦ Use of physiological lipids 
♦ Avoidance of organic solvents 
♦ Improved bioavailability 
♦ Chemical protection of labile incorporated compounds 
♦ Very high long term stability 
♦ Application versatility 
Disadvantages of SLNs: 
♦ Particle size increase 
♦ Polymorphic transitions 
♦ Gelation tendency 
Methods of Preparation of SLNs: 
High Pressure Homogenization: 
  It is a reliable and powerful technique, which pushes a liquid with 
high pressure (100-2000bar) through a narrow gap. 
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 Hot homogenization: 
 It is carried out at temperature above the melting point of lipid. 
 
 Cold homogenization: 
 It has been developed to overcome various problems associated with hot 
homogenization such as temperature induced drug degradation, drug distribution into 
the aquous phase during homogenization, complexity of crystallization step of 
nanoemulsion leading to several modification and/super cooled melts. 
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Ultrasonication/ High speed homogenization: 
 SLNs are also prepared by ultrasonication/high speed homogenization 
techniques.  For smaller particle size combination of both ultrasonication and high 
speed homogenization is required. 
Solvent Emulsification diffusion method: 
 The particles with average diameters of 30-100nm can be obtained by this 
technique.  Avoidance of heat during the preparation is the most advantage of this 
technique. 
 
Supercritical fluid method: 
 This is an alternative method of preparing SLNs by particles from gas 
saturated solutions (PGSS). 
Spray drying method: 
 It is an alternative process to lyophilization.  It recommends the use of lipid 
with melting point more than 70ºC.  Best results were obtained with SLN of 1% in a 
solution of trehalose in water or 20% in ethanol water mixure. 
Double emulsion method: 
 In this method drug is encapsulated with a stabilizer to prevent the 
partitioning of drug in to external water phase during solvent evaporation in external 
water phase of w/o/w double emulsion. 
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Precipitation method: 
 The glycerides are dissolved in an organic solvent and the solution will be 
emulsified in an aquous phase.  After evaporation of the organic solvent the lipid will 
be precipitated forming nanoparticles. 
Film ultrasound dispersion: 
 The lipid and drug were put into suitable organic solution, after 
decompression, rotation and evaporartion of the organic solutions, a lipid film is 
formed, then the aquoux solution which includes the emulsion was added. 
Secondary Production Step: 
Freeze drying: 
 Lyophiilization is a promising way to increase chemical and physical stability 
over extended periods of time.  Transformation in to the solid state would prevent the 
Oswald ripening and avoid hydrolytic reactions. 
Spray drying:  
 Spray drying might be an alternative procedure to lyophilisation in order 
transforms an aqueous SLNs dispersion in to dry product. The lipids with melting 
point at temperature greater than 70
º
C had been recommended for spray drying.            
(Shagufta Khan et al, 2012) 
Drug release from SLN: 
 
Figure 6 
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Homogenous matrix model: 
 In this with many drugs being present in amorphous clusters or molecularly 
dispersed is mainly obtained when incorporating highly lipophillic drugs in to SLN 
using hot homogenization method or by avoiding drug solubilising surfactants. 
Drug enriched shell with lipid core: 
 The drug enriched shell with lipid core model will be obtained when 
performing the production.  During production, the drug is partition to the water 
phase and upon cooling the lipid precipitate first forming a practically drug free lipid 
core due to phase separation.  At the same time the drug re-partitions in to the 
remaining liquid lipid phase and drug concentration in the outer shell increasing 
gradually.  Finally drug enriched shell crystallizes.  The amount of drug partitioning 
will increase with increase of aquous solubility of drug. 
Drug enriched core with lipid shell: 
 A drug enriched core obtained when dissolving drug in the lipid melts at or 
dose to its saturation solubility.  In here, cooling of the formed nanoemulsion will 
lead to supersaturation of drug in melted lipid and on further cooling will lead to 
precipitation of lipid surrounding the drug enriched core as a membrane, due to 
increased diffusional distance and hindering effect of surrounding solid lipid shell, 
the carrier system shows sustained release profile.   (Meghana S. Kamble et al, 2012) 
Factors determining the loading capacity of the drug in the lipid: 
• Solubility of the melted lipid. 
• Miscibility of the drug melt in the lipid melt. 
• Chemical and physical structure of solid lipid matrix. 
• Polymorphic state of lipid material. 
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The pre-requisite to obtain a sufficient loading capacity is a sufficiently high 
solubility of the drug in the lipid melt. Typically the solubility should be higher than 
required because, it decreases when cooling down the melt and might be even lower 
in the solid lipid. To enhance the solubility in the lipid melt one can add solubilizers. 
In addition, the presence of mono and di-glycerides in the lipid used matrix material 
promotes drug solubilization. The chemical nature of the lipid is also important 
because lipids which form highly crystalline particles with a perfect lattice lead drug 
expulsion.            (Abdul Hasan Sathali A et al, 2012) 
Routes of Administration: 
♦ Oral administration 
♦ Parentral administration 
♦ Rectal administration 
♦ Nasal administration 
♦ Respiratory administration 
♦ Ocular administration 
♦ Topical administration 
     (Shah Chandni V et al, 2011) 
Applications of SLNs: 
♦ SLNs for parasitic diseases 
♦ SLNs as potential new adjuvant for vaccines 
♦ SLNs in cancer chemotherapy 
i. SLNs as targeted carrier for anticancer drug to solid tumor 
ii. SLN in breast cancer and lymph node metastases 
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♦ SLNs for malarial disease 
♦ SLNs in treatment of tuberculosis 
♦ SLNs for brain targeted drug delivery 
♦ SLNs for improved delivery of antiretroviral drugs to the brain 
♦ SLNs for lung targeted drug delivery 
♦ SLNs for lymph targeting 
♦ SLNs for ultrasonic drug and gene delivery 
♦ SLNs for delivery of peptides and proteins 
♦ SLNs in cosmetical and dermatological preparations  
         (Krishna Sailaja A et al, 2011) 
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ORAL DRUG DELIVERY SYSTEM 
Oral drug delivery is most widely utilized route of administration among all 
the routes that have been explored. An ideal drug delivery system should deliver an 
appropriate amount of drug to the desired site with a desired rate to optimize the drug 
therapy. Due to the considerable therapeutic advantages over conventional oral drug 
delivery dosage forms, various oral controlled release dosage forms have been 
developed. 
Controlled Drug Delivery System: 
 The term controlled release on the other hand, has a meaning that goes 
beyond the scope of sustained drug action. It also implies a predictability and 
reproducibility in the drug. 
Advantages of controlled drug delivery system 
♦ Decreased incidence and/or intensity of adverse effects and toxicity 
♦ Better drug utilization 
♦ Controlled rate and site of release 
♦ More uniform blood concentration 
♦ Improved patient compliance 
♦ Reduced dosing frequency 
♦  prolonged therapeutic effect 
♦ A greater selectivity of pharmacological activity. 
Gastroretentive Drug Delivery System: 
 Dosage forms that can be retained in the stomach are called gastroretentive 
drug delivery system (GRDDS). These are the systems which can remain in gastric 
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region for several hours and significantly prolongs the gastric residence time of drug. 
After oral administration, such a delivery system would be retained in stomach. 
Types of Gastroretentive Delivery Systems: 
♦ Bioadhesive system 
♦ Floating system 
♦ Unfolding system 
♦ Size increasing system 
♦ Density controlled system       
            (Aashima Hooda et al, 2012) 
 
Figure 7 
MUCOADHESIVE DRUG DELIVERY SYSTEM 
 A bioadhesive can be defined as a substance with the ability to interact with 
biological materials and is capable of being retained there. It involves the use of 
bioadhesive polymers which are usually macromolecular, hydrophilic gelling 
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substances with numerous hydrogen bond forming groups, such as carboxyl, 
hydroxyl, amide and sulfate groups (e.g., crosslinked polyacrylic acids, sodium 
carboxymethyl cellulose, sodium alginate and carrageenan) that can adhere to the 
epithelial surface of the GIT. 
 
Figure 8 
                          (Aashima Hooda et al, 2012) 
Theories of Mucoadhesion 
Several bioadhesion theories have been discussed.  
1) Electronic theory 
It defined as the electron transfer from contact of an adhesive polymer with a 
glycoprotein network; they form an electrical interface at adhesive polymer and 
glycoprotein network. Adhesion can produce by attractive forces across the double 
layer.  
2) Absorption theory  
Absorption theory is defined as the cause after initial contact between two 
surfaces that is material surface because a force formed between two surfaces, the 
force is two types of chemical bond that is,  
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i. Primary chemical bond of covalent bond: they are high strength so they 
cause permanent bonds.  
ii. Secondary chemical bond has types of force of attraction like electrostatic 
force, Vander Waals forces, hydrogen and hydrophobic bonds.  
3) Wetting theory 
They are only beneficial for liquid bioadhesive systems, analyses adhesive 
and contact behaviour means they have ability of a liquid or a paste to spread over a 
biological system. 
The equation is 
Wa= Ya + Yb – Yab  
Where,   Wa = work of adhesion = energy/cm 2 
a and b - biological membrane  
Work of cohesion equation is  
Wc = 2YA – (Y A + Y AB)  
Wc = 2Y A or Y B  
Bioadhesive material B spreading on a biological substrate A so spreading 
coefficient that is,  
SB/A = YA – (YB + YAB)  
SB/A should be positive for a bioadhesive material to adhere to a biological 
membrane.  
4) Diffusion Theory: 
This theory provides the information that the polymer chains and the mucus 
mix to a sufficient depth to form a semi permanent adhesive bond. The polymer 
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chains penetrate the mucus depends on the diffusion coefficient and the time of 
contact. 
5) Fracture Theory: 
This theory related for difficulty of separation of two surfaces after adhesion, 
The equation,  
G = (E e/L) 1/2  
E = Young‟s formula of elasticity  
e = Fracture energy  
L= Critical crack length  
                (Chein Y. W. - Novel drug Delivery System) 
Gastric emptying 
The  process  of  gastric  emptying  occurs  during both  fasted  state  and  fed  
state  however, the pattern of motility differs markedly in these two states. In the 
fasted state, it is characterized by an inter digestive  series  of  electrical  events, 
which  propagate  both  through  stomach  as well  as small  intestine  every  2-3  
hours. This activity is called as inter digestive myo electric complex, and is often 
divided into four consecutive phases.  
 Phase I 
It is a quiet period lasting from 30-60 min, with rare contractions.  
 Phase  II 
It  is  a  period  of  similar  duration  consisting  of  intermittent  action                                
potentials  gradually  increases  an intensity and frequency as phase 
progresses. 
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 Phase III 
It is a short period of intense, large regular contractions lasting from 
10-20 min. As it serves to sweep undigested materials out of stomach and 
down in small intestine. It is termed as „housekeeper waves‟. As the phase III 
of one cycle reaches the distal part of small intestine, the phase III of next 
cycle begins in duodenum.     
 Phase IV 
It is a brief transitional phase that occurs between phase III and phase 
I of two consecutive cycles. In the fed state, the gastric emptying rate is 
slowed since the onset of IMC is delayed. 
Types of Mucoadhesive Dosage Forms: 
♦ Tablets 
♦ Gels & ointments 
♦ Films 
♦ Patches 
Factors Affecting Mucoadhesion: 
♦ Molecular weight 
♦ Cross linking & Swelling 
♦ Hydrophilicity 
♦ Concentration of active polymer 
♦ pH 
♦ Spatial conformation 
CHAPTER - 2 
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CHAPTER – 2 
LITERATURE REVIEW 
 
Hassan M. Ghonaim et al., 2013, designed and characterized glyceryl 
monosterate solid lipid nanoparticles[SLN]. Glyceryl monosterate SLN containing 
dibenzoyl peroxide, erythromycin base and triamicinolone acetonide as model 
drugs were prepared by hot homogenization method. The prepared SLNs were 
characterized by different physical and imaging methods. Thus SLNs with and 
smooth surface particle size having high encapsulation could be obtained by hot 
homogenization technique. 
Jaspreet Randhawa et al., 2013, has done a review on high melting lipid based 
approach for drug delivery.  Poor solubility of newly developed drug molecules is 
the main problem in recent drug discovery research, so novel drug delivery 
approaches are being used to deliver these molecular entities for pharmacological 
action.  Colloidal carriers have been used to administer poorly soluble drug, but 
solid lipid nanoparticles are found to be most reliable carriers for this type of drugs 
due to its advantage over carriers.  SLNs have the potential to solve the drug 
delivery problems with safe excipients used in its formulation.  In this review all 
the aspects of SLNs production, stability, characterization, differentiation based on 
route, preservation and storage have been discussed. 
Pinitphon Prombutara et al., 2012, formulated nisin loaded solid lipid 
nanoparticles [SLN] for sustained anti microbial activity. Here, nisin – a natural 
antimicrobial agent used as a preservative in food was encapsulated in imvitor 900 
based SLN by high pressure homogenization. Nisin loaded SLNs had particle size 
of 159 ± 6.4 to 167 ± 8.6 nm and had a zeta potential of - 28.3 ± 0.15 to - 29.2 ± 
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0.12 mV and entrapment efficiency of 69.2 ± 0.04 to 73.6 ± 0.04 % . Finally it was 
concluded that nisin from SLNs showed better antimicrobial action for 20 to 15 
compared to free nisin.  
Yitao Wang et al., 2012, has developed emodin loaded solid lipid nanoparticles. 
The objective of the present study was to prepare and evaluate emodin loaded 
SLNs and evaluate their anti tumor activity in vitro. Poloxamer 188 and tween 80 
were used as surfactants. The prepared SLNs were characterized for their particle 
size, drug entrapment efficiency, zeta potential, stability and in vitro drug release 
studies. MTT assay showed emodin- SLN could enhance in vitro cytotoxicity 
against human breast cancer cell line MCF-7 and MDA-MDB-231 cells flow 
cytometric analysis showed more significant cell cycle arrest effect in MCF-7. In 
vitro drug release showed 72 hour drug release from SLN, exhibiting a sustained 
action. 
Yaping Li PhD et al., 2012, has developed solid lipid nanoparticles loaded with 
candesartan cilexetil to enhance oral bioavailability. Candesartan – a poorly 
aqueous soluble, very low orally absorbing drug was encapsulated in SLN by film 
homogenization technique. The prepared SLNs were characterized for their 
particle size, entrapment efficiency (91.33%) the pharmacokinetic results indicated 
improved oral bioavailability of candesartan over 12- fold in SLNs. 
De Pintu Kumar et al., 2012, has done project on formulation and evaluation of 
solid lipid nanoparticles of poorly water soluble model drug ibuprofen. Ibuprofen 
was encapsulated in SLN by hot homogenization method to enhance solubility and 
dissolution rate. Stearic acid used as lipid matrix and phospholipon 80 H was used 
as surfactant and tween 80 as stabilizer. Prepared SLNs were characterized for size 
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distribution, entrapment efficiency, drug release and stability. In vitro drug release 
studies showed higher release through dialysis membrane than pure drug. Hence 
SLNs prove to be a more efficient carrier for ibuprofen. 
Kesavan Bhaskar Reddy et al., 2012, has done formulation and in vitro 
assessment of itraconazole loaded solid lipid nanoparticles for topical delivery. 
Itraconazole – a poorly water soluble drug was encapsulated in SLNs by hot 
homogenization method, using dynasan 118, phospatidylcholine and polysorbate 
80 at varied concentrations. The formulated itraconazole-SLNs were evaluated for 
their particle size, zeta potential, entrapment efficiency, DSC, FTIR, P-XRD 
studies, stability, in vitro and in vivo permeation studies. The optimized 
formulation showed drug release of 83.4% and drug permeation of 1173µg/cm
2
 
after 24 hours. Results showed that incorporation of drug  into SLNs showed 
better drug release. 
Yamasai Madhusudan Rao et al., 2012, formulated atorvastatin loaded solid 
lipid nanoparticles by hot homogenization followed by ultrasonication technique. 
The mean particle size. Poly dispersity index, zeta potential and entrapment 
efficiency were found to be 50 ± 6.2 nm, 0.08 ± 0.011, 10.40 ± 4.68 mV and 88.7 
± 6.08% respectively. In vitro drug release showed controlled release over a period 
of 24 hours, comparing to pure drug. Stability studies showed that there was no 
physical instability over a period of 3 months. 
Priyanka K, Abdul Hasan Sathali. A, 2012, developed preparation and 
evaluation of montelukast sodium loaded solid lipid nanoparticle. Montelukast – a 
poor orally available, high presystemically metabolized drug was chosen to 
formulate SLN by hot homogenization followed by ultrasonication technique. 
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Compritol ATO 888, stearic acid, and glyceryl monosterate were used as lipid 
matrix and polyvinyl alcohol as surfactant. The formulated SLNs were 
characterized for their drug content, entrapment efficiency, in vitro drug release, 
particle size analysis, scanning electron microscopy, FTIR, DSC and stability 
studies. Entrapment efficiency was found to be 42% to 92%, in vitro drug release 
studies showed cumulative drug release of 59% containing stearic acid and lowest 
of 28% containing compritol after 12 studies. From all these studies SLNs of 
compritol ATO 888 showed best lipid formulation. 
Kaushik. M et al., 2012, formulated and evaluated solid lipid nanoparticles of 
aceclofenac. Aceclofenac – a poorly soluble drug wass encapsulated using 
glyceryl behenate as lipid carrier and poloxamer 188 as surfactant by solvent 
injection method. The mean particle size measured by laser diffraction was 226.9 
nm and surface morphology was determined by scanning electron microscopy. 
The entrapment efficiency was found to be 90% and in vitro drug release was 
found to be 90.22%. 
Shagufta Khan et al., 2012, developed dithranol loaded solid lipid nanoparticles. 
Dithranol – a poorly soluble drug was encapsulated in SLNs by adaptation of lipid 
dispersions method. Appropriate analytical methods were needed for 
characterization of SLNs such as particle size, percentage entrapment, percentage 
drug loading and percentage yield. Morphology of SLNs were characterized with 
scanning and transmission electron microscopy. In vitro drug release studies were 
carried out using HIMEDIA dialysis bag. In conclusion, SLNs presented were wll 
suited for several applications including drug delivery. 
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Lakshmi Sirisha Kotikalapudi et al., 2012, formulated and evaluated 
domperidone solid lipid nanoparticles. SLNs  were prepared by hot 
homogenization followed by ultrasonication technique. The prepared SLNs were 
characterized for particle size, polydispersity index, zeta potential, entrapment 
efficiency and in vitro drug release. The mean particle size, poly dispersity index, 
zeta potential and entrapment efficiency of optimized formulation were found to 
be 56 nm, 0.154, 34 mV, 98.5%. P-XRD and DSC studies showed that drug was in 
amorphous state. In vitro drug release studies showed controlled drug release for a 
period of 48 hours. Thus, fairly spherical shaped, stable and controlled release 
domperidone-SLNs could be prepared by hot homogenization followed by 
ultrasonication method. 
Rassoul Dinarvand et al., 2012, improved antimicrobial activity if rifampin using 
soid lipid nanoparticles. Rifampin loaded SLNs were prepared by modified micro 
emulsion method. The prepared SLNs were characterized for their particle size, 
zeta potential, encapsulation efficiency, morphology and antibacterial activity 
against mycobacterium fortuitum. The resulting SLNs were spherical with 
diameter about 100 nm, with low negative zeta potential and encapsulation 
efficiency of 82%, with sustained release for 72 hours. The minimum inhibitory 
concentration of rifampin -SLNs were eight times less than free rifampin. Thus it 
was concluded that SLNs show a promising vehicle for enhanced antimicrobial 
effect. 
Subhra Prakash Bhattacharya et al., 2012, developed flurbiprofen loaded solid 
lipid nanoparticles. Flurbiprofen – a poorly water soluble drug was encapsulated in 
SLNs by modified solvent injection method, using different ratios of stearic acid 
CHAPTER – 2             LITERATURE REVIEW 
MUCOADHESIVE TABLETS OF SLN LOADED WITH DRUG Page 25 
 
and tripalmitin as lipid matrix and pluronic F-68 as emulsifier. The main aim of 
the project was to optimize the prepared SLNs by response surface methodology. 
A central composite design for 2 factors at 3 levels each was employed to 
systemically optimize particle size, drug entrapment efficiency and drug release in 
1 hour. The effect of 2 factors on various response variables helped in finding 
optimum formulation with excellent distribution profile and stability. 
Abdul Hasan Sathali A et al., 2012, has done a review on Solid Lipid 
Nanoparticles.  In this review, a broad treatment of SLNs discussing their aims, 
production procedures advantages, limitations and their possible remedies.  Due to 
their unique size dependent properties, lipid nanoparticles offer possibility to 
develop new therapeutics.  Solid Lipid Nanoparticles, the forefront of rapidly 
developing field of nanotechnology has several potential applications in drug 
delivery and research.  Appropriate analytical techniques for characterization of 
SLN like photon correlation spectroscopy, scanning electron microscopy, 
differential scanning colorimetry were highlighted. 
Shailesh S. Chalikwar et al., 2012, formulated nimodipine loaded SLN a highly 
lipophilic anti-hypertensive drug. SLN prepared with palmitic acid, poloxamer 
188 and soya lecithin as lipid, surfactant and co-surfactant by high pressure 
homogenisation. The pharmacokinetic study of optimized SLNs conducted in male 
albino wistar rat shows 2.08-fold increased in relative bioavailability than that of 
NMD solution, when administrated orally. SLN were a promising drug delivery 
for transporting the lipophilic drugs to the intestinal lymphatic region resulted in 
increased oral bioavailability of drug and reduction in dosing frequency. 
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Ramteke K.H et al., 2012, has done a review on solid lipid nanoparticles (SLNs).  
SLNs are the colloidal drug carrier system, suitable for intravenous administration, 
consisting of spherical solid lipid particles in nanometer size ranges.  Different 
production methods production methods which are suitable for large scale 
production and the applications are also discussed here.  Characterization using 
photon correlation spectroscopy, scanning electron microscopy, differential 
scanning calorimetry is also described.  Thus the importance of SLNs, if 
appropriately investigated, may solve many complex diseases. 
Shaguft Khan et al., 2012, has done a review on solid lipid nanoparticles.  SLNs, 
due to their unique size dependent properties, offer the possibility to develop new 
therapeutics.  The ability to incorporate drugs into nanocarriers, offer a new 
prototype in drug delivery that could be used for secondary and teritiary levels of 
drug targeting.  Different production methods which are suitable for large scale 
production and applications of solid lipid nanoparticles are described.  Appropriate 
analytical techniques for characterization of SLN like photon correlation 
spectroscopy, Scanning electron microscopy and differential scanning calorimetry 
are discussed.  Hence SLNs hold great promise for reaching the goal of controlled 
and site specific drug delivery.  
E. B. Souto et al ., 2011, developed lopinavir loaded solid lipid nanoparticles for 
intestinal targeting. The poor orally available lopinavir was encapsulated in 
glyceryl behenate based SLNs by hot homogenization followed by ultrasonication 
method. SLNs were characterized using differential scanning colorimetry, wide 
angle x-ray scattering and atomic force microscopy for their solid characteristics 
and homogenous distribution. From intestinal lymphatic transport study, SLNs 
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increased cumulative percentage dose of lopinavir, which was 4.91 fold higher 
than drug suspended in methyl cellulose (0.5%) as suspending agent. The AUC of 
lopinavir-SLN was 2.91 fold higher than lopinavir in methyl cellulose. 
Accelerated stability studies showed that there was no significant change in mean 
particle size and Polydispersity index after storage at 25 ± 2ºC / 60 ± 5% RH. 
Shelf life of optimized formulation was found to be 21.46 months. 
Silva A.C. et al., 2011, prepared risperidone- loaded solid lipid nanoparticle for 
oral administration by hot high pressure homogenisation and ultrasound. Prepared 
SLN showed the particle size in nanometer range, predicted good long term 
stability. Commercial oral formulations (suspension and tablets) of risperidone 
maximum concentration of 4mg since required a frequent dose administration. 
Concluded that two lipids compritol ATO 888 and Imwitor 900K suitable for 
RISP-loaded SLN. For a drug ≥4% present as insoluble drug carrier was observed. 
Imwitor 900K was selected for production of 3%(w/w) RISP-loaded SLN and the 
lipid tested for oral delivery. 
Wen Zhong Zhou et al., 2011, prepared and evaluated ofloxaxin loaded palmitic 
acid solid lipid nanoparticles. SLNs were prepared by hot homogenization and 
ultra sound method. SLNs were characterized for their particle size, encapsulation 
efficiency, Polydispersity index, loading capacity and zeta potential, which were 
found to be 156.33 ± 7.51 nm, 4.40 ± 0.16%, 0.26 ± 0.04, 4.40 ± 0.16%, -22.7 ± 
1.40 mV respectively. Pharmacokinetic results demonstrated that SLNs increase 
bioavailability by 2.27 fold and extended mean residence time of drug from 10.50 
hours to 43.44 hours. The overall results indicate SLNs to be promising drug 
delivery to enhance pharmacological action of ofloxaxin. 
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Min – Shing Chen et al., 2011, suggested the delivery system of solid lipid 
nanoparticles could enhanced its oral bioavailability. Monostearin and Soya 
lecithin were used as lipid and emulsifiers. The bioavailability of puerarin 
formulated as phosphor lipid complex was 1.46- fold higher than that with 
puerarin suspended in water. Puerarin was incorporated into SLN, the relative 
bioavailability of puerarin was 310% and indicated that incorporated into SLNs 
enhanced the absorption of puerarin after oral administration. The decreased 
excretion in feces and increased excretion of puerarin in urine suggested the 
improved absorption after entrapped into nanoparticles. 
Maria Antonietta Casadei et al., 2011, designed the system SLN dextran 
hydrogel containing ketconazole for topical delivery. Ketaconazole – a broad 
spectrum anti fungal agent suffers from poor water solubility and chemical 
degradation, which was overcome by incorporating the drug into SLNs for topical 
delivery. All SLN formulations had good entrapment properties and were able to 
protect drug from UV degradation. Antifungal efficacy was tested against Candida 
albicans, whereas skin tolerability was tested on rabbits. 
Marreto R.N. et al., 2011, developed SLN and NLC with high drug load of 
topotecan. SLNs were prepared by microemulsion technique using Stearic acid 
and oleic acid as solid and liquid lipids, soya lecithin sodium, taurodeoxycholate 
as emulsifiers. Homogenous, small sized, negatively charged lipid nanoparticle 
with high entrapment efficiency and drug load was obtained. SLNs showed slower 
degradation in vivo provided better control of drug release and protected 
encapsulated drug. SLN and NLC showed no difference with respect to all 
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parameters of mean particle size, polydispersity index, zeta potential, entrapment 
efficiency and drug loading. 
Young Jik Kwon et al., 2011, has done review on ‘Nanoantibiotics’.  The main 
drawbacks for conventional antimicrobial agents were the development of 
multiple drug resistance and adverse side effects.  Drug resistance enforces high 
dose administration of antibiotics, often generating intolerable toxicity, 
development of new antibiotics and requests for significant economic, labour and 
time investments.  Several classes of pathogenic microorganisms developed 
resistance against several antibiotics, which could be overcome by antimicrobial 
nanoparticles and nano sized carriers.  Thus, this review had summarized 
emerging efforts in combacting against infectious disease, particularly using 
antimicrobial nanoparticles and antibiotics delivery systems as new tools to tackle 
the current challenges in treating infectious disease. 
Vandana B Patravale et al., 2011, has done a review on overcoming poor oral 
bioavailability using nanoparticles formulations.  Oral delivery of drugs with poor 
aqueous solubility and poor enzymatic and/or metabolic stability was very 
challenging.  However, the advent of nanotechnology has revolutionized the field 
of oral drug delivery.  In this review, an overview of various nano architectures 
such as nanosuspensions, lipid and polymeric nanoparticles, inorganic nano 
structures had been discussed and their advantages and challenges associated with 
their delivery were also discussed. 
Lireni C Humtsoe et al., 2011, has done a review on Brain delivery by solid lipid 
nanoparticles for CNS drugs.  Brain has been the most delicate organ in the body 
and drugs accessing to brain has been severely limited by some factors such as 
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blood brain barrier, P-gp efflux mechanisms.  This review highlights about the 
advantages of SLN over the other colloidal carriers as well as the advantages of 
nanoparticles for brain targeting, some proposed mechanisms to cross blood brain 
barrier, incorporation models and release of drugs form SLN. 
Jithan Aukunuru et al., 2010 designed systemic delivery of diclofenac sodium 
after topical application of gels incorporated with drug loaded solid lipid 
nanoparticles. Diclofenac sodium-SLNs were prepared by hot homogenization 
followed by sonication technique and the prepared SLNs were incorporated in 
freshly prepared carbopol gel. The gels enriched with SLNs sustained the drug 
release for 24 hours both in vitro and in vivo. Results suggested enhancement in 
systemic delivery of diclofenac sodium with gels incorporating SLNs. 
Arvind k Bansal et al., 2010, has done a review on self emulsifying drug delivery 
system to improve bioavailability.  Through this delivery system, followed by 
their oral administration, they rapidly dispense in gastro intestinal fluids, gidding 
micro/ nano emulsified drug can easily be absorbed through lymphatic pathways 
by passing hepatic first pass metabolisms owing to their smaller particle size.  The 
different types of self emulsifying formulations, their formulation, 
characterization, biopharmaceutical aspects, advantages and recent development 
are discussed.  Finally self emulsifying drug delivery systems show a promise for 
better drug delivery of poorly bioavailable drugs. 
A Malzert Freon et al., 2010, has done a research on influence of a solubility 
enhancer on formulation of lipidic nanoparticles with improved drug loading rates.  
Here a poorly water and lipid soluble drug is encapsulated in lipidic nano 
formulation without using organic solvents, by adding a solubility enhancer such 
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as Labrasol, through low energy phase inversion temperature method.  Labrasol 
does not prevent phase inversion and it takes part in the micro emulsion 
structuring, probably bicontionous type.  From results of partial least squaring 
pseudo ternary liagzoms, the nanoparticles present a core shell structure, were 
labrsol is all encapsulated and contributes to formation of oily liquid core of 
nanoparticle.  So highly drug loaded lipidic nanocarriers were developed without 
using the silightest organic solvent trace and making it easy. Possible dose 
adjustment could also be achieved. 
Hoo – Kyun Choi et al., 2009, formulated solid lipid nanoparticles loaded with 
doxorubicin. SLNs were prepared by solvent emulsification – diffusion method. 
The mean particle size, entrapment efficiency, drug loading were found to be 199 
nm, 67.5 ± 2.4% and 2.8 ± 0.1% respectively. In conclution, SLNs with small 
particle size, high entrapment efficiency and relative high drug loading for 
doxorubicin could be obtained by this method. 
Anil K. Sharma et al., 2009, developed solid lipid nanoparticles of lamivudine 
for brain targeting. Lamivudine, the most widely used drug for treatment of AIDS, 
was incorporated into SLNs by emulsion solvent diffusion technique. The 
optimum rotation speed for better drug entrapment and percentage yield was in the 
range of 1000 to 1250 rpm. The in vitro drug release from optimized formulation 
was found to be 40% - 50% in PBS and SGF for 10 hours. After 24 hours more 
than 65% of drug was released from all formulations in both mediums, meeting 
the requirement for drug delivery for prolonged period of time. 
Andrew Laxley et al., 2009, has done a review on solid dipid nanoparticles.  Here 
poorly water soluble drugs such as class II and III BCS drugs, which have poor 
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bioavailability are formulated in to a drug delivery vehicle that specifically targets 
tissue or cells to maximize therapeutic index.  A common formulation approach 
with such compounds is focus on creating and stabilizing very small particles of 
the drug in an attempt to increase the surface area available for dissolution in vivo, 
and hence the rate of dissolution and consequently plasma or tissue levels of drug. 
Seitaro Kamiya et al., 2008, designed the nifedipine lipid nanoparticle and 
investigated the prepared formulation without using any organic solvents. A mean 
particle size of approximately 50nm could be prepared without organic solvents by 
a combination of roll milling and high pressure homogenisation. The X-ray 
diffraction peak of sample presented identical position and showed no peak shift 
was induced by interaction with lipid. The particle size of suspension was 
maintained for long time by adding gelatin powder to the NI-lipid suspension. The 
mean particle size of 55nm was retained as nanoparticle. 
Linden H et al., 2007, has given a conference report about poor solubility issues.  
The major challenges in oral delivery of new drugs such as absorbtion, sufficient 
and reproducible bioavailability are discussed. During discovery of new 
technologies, tremendous knowledge has been accumulated on biological factors 
like transporters metabolizing enzymes and efflux systems as well.  Research tools 
and technologies have been and are will be developed to assess the impact of these 
factors on drug absorption for new chemical entities.  The impact of compounds 
with poor solubility on analytical evaluation, prediction of oral absorption, 
substance selection, material and formulation stratagies and development are 
discussed here. 
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Antonio J Almeida et al., 2007, has done a review on solid lipid nanoparticles as 
a delivery system for peptides and proteins.  Solid lipid particulate systems have 
been sought as alternative carriers for therapeutic peptides, proteins and antigens.  
The research work developed in area confirms that under optimized conditions 
they can be produced to incorporate hydrophobic or hydrophilic proteins.  Proteins 
and antigens intended for therapeutic purposes may be incorporated or adsorbed 
on to SLNs and further administerd by parentral routs or by alternative routs such 
as nasal and pulmonary.  Formulation of SLN confers improved protein stability 
avoids proteolytic degradation as well as sustained release of incorporated 
molecules.  So far SLNs prove to be a promising tool for administering protein 
molecules. 
Xiangliang yang et al., 2005,
 
investigated the anti-inflammantory activity and 
hepatotoxicity of triptolide loaded SLN. The anti-inflammantory activities of 
triptolide – SLN were stronger than the free triptolide. Oral observation occurred 
and nanoparticles were likely to cross the gastro-intestinal barrier to deliver their 
drug content in the blood, lymph or target organ. Lymphatic up take by the M cells 
of the teyer’s batches appears to be a major sight of translocation of solid 
particulates. It depended on particle characteristics such as size or surface 
properties. It was concluded that solid lipid nanoparticle delivery system enhanced 
triptolide absorption, increased its bioavailability and obtained sustained, 
controlled effects. 
Sanjeeb K Sahoo et al., 2003, has done a review on nanotech approaches to drug 
delivery and imaging.  Nanotechnology is expected to create innovations and play 
a critical role in various biomedical applications not only in drug delivery by also 
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in molecular imaging, biomarkers and bio sensors.  Target specific drug therapy 
and methods for early diagnosis of pathologies are the priority research areas 
where nanotechnology would play a vital role.  In this review, various 
nanotechnology based drug delivery and imaging approaches and their economic 
impact on pharmaceutical and biomedical industries are discussed. 
Sven Gohla et al., 2000, has done a review on solid lipid nanoparticles for 
controlled drug delivery.  Solid lipid nanoparticles were first introduced in 1991 as 
an alternative carrier system to traditional colloidal carriers.  This review have 
presented the state of art regarding production techniques for SLN, drug 
incorporation, loading capacity and drug release, especially focusing on drug 
release mechanisms. Relevant issues for the introduction of SLN to the 
pharmaceutical market, such as status of excipients, toxicity, tolerability aspects 
and sterilization and long term stability inducing industrial large scale production 
were also discussed.  The potential of SLN to be exploited for the different 
administration routes were highlighted. 
Sven H. Gohla et al., 2000, formulated vitamin A loaded solid lipid nanoparticles. 
Vitamin A loaded SLNs were incorporated in hydrogel and o/w cream and tested 
with respect to their influence on drug penetration into porcine skin. Because of 
polymorphic transition of lipid carriers with subsequent drug expulsion following 
the application to skin, the drug localizing action appears to be limited for 6 to 24 
hours. Best results were obtained with retinol-SLN incorporated in o/w cream 
retarding drug expulsion. 
Gujjar Chaitanya Yogananda et al., 2013, developed muoadhesive formulation 
of Quetiapine fumarate using non-gelling polymer.  Mucoadhesive tablets were 
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prepared using non-gelling polymers such as lambda carrageenan and effective 
thickner propylene glycol alginate, by dry granulation techniques.  Dissolution 
profiles were compared with marketed preparations, in which formulation with 
propylene glycol alginate had comparable dissolution profile to that of marketed 
formulation. 
Rao B Umamaheswara et al., 2012, designed and characterized sustained release 
mucoadhesive tablet o glipizide.  Here, glipizide a short biological half life drug 
was formulated in to mucoadhesive tablets using different combination of 
polymers such as HPMC K4 M, HPMC K100 M, Carbopol 71G by wet 
granulation method.  Preformulation studies and post compression evaluation were 
carried out for the formulations.  Hence mucoadhesive tablets of glipizide show a 
promising improvement for diabetic administration. 
Vitaliy V Khutoryanskiy et al., 2012, has formulated chitosan based 
mucoadhesive tablets for oral delivery of ibuprofen.  Chitosan and its half 
acetylated derivative have been compared as excipients.  Powder formulation for 
tableting was prepared by either co-spray drying or by physical co-grinding.  
Polymer-drug interactions and degree of drug crystallinity were assessed by 
infrared spectroscopy and differential scanning calorimetry. Mucoadhesive 
property of prepared tablets was analyzed by their detachment from pig gastric 
mucosa over a range of pH. Increased polymer-drug interactions were seen for 
spray dried particles.  Higher drug loading was observed for chitosan based 
microparticles than half acetylated samples.  Swelling and drug release was 
observed with half acetylated chitosan tablets.  These results indicate a potential 
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sustained drug delivery for oth chitosan and its half acetylated derivative as 
mucoadhesive tablet excipients. 
Goswami Dhruba Sankar et al., 2011, has formulated and evaluated 
mucoadhesive tablets of famotidine by wet granulation method.  Since the drug 
has a short halft life, it was formulated in to mucoadhesive tablets using natural 
and synthetic polymers.  Evaluations were done for the fabricated tablets.  In vitro 
drug release studies showed formulation containing HPMC K4 M and tragacanth 
having better muco adhesive property.  Thus the present investigation showed the 
combination of HPMC K4 M and traganch as hydrophilic polymers for 
preparation of famotidine mucoadhesive tablets. 
Inderbir Singh et al., 2011, has formulated and evaluated muucoadhesive matrix 
tablets of Taro gum by direct compression method.  The prepared tablets were 
evaluated for bioadhesive strength and invitro dissolution parameter.  The 
mucoadhesive detachment force was found to increase with taro gum 
concentration increase.  Invitro drug release follows first order kinetics and shows 
best linearity with higuchi mode.  PVP K 30 has indirect effect on all the factors 
byincreasing tenstile strength and making the tablet firm and intact. 
Remeth Dias et al., 2010, studied in vitro absorbtion of mucoadhesive tablets of 
acyclovir.  In here the absorbtion of acyclovir was improved using permeation 
enchancer such as sodium lauryl sulphate. From the perfusion studies of intestinal 
model, the permeability of mucoadhesive tablets were found to increase with 
increase in sodium lauryl sulphate (4%) comparing to marketed formulations.  
Thus mucoadhesive tablets with permeation enhancers shows promising 
developments in increasing bioavailability of drugs. 
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Akant Priyo Singla et al., 2010, characterized mucoadhesive tablets of 
ciprofloxacin, by wet granulation technique.  Combination of hydrophilic and 
hydrophobic polymers was used and further evaluation studies were performed for 
the mucoadhesive tablets.  In vitro release studies showed formulation containing 
HPMC and tragacanth had better mucoadhesive property.   Since fluroquinolones 
appear to have effect in patients not responding to trimethoprim and 
sulfamethaxazole.  Mucoadhesive tablets of ciprofloxacin prove to be potential in 
many disease conditions. 
Mahesh D Chavanpatil et al., 2006, has formulated novel sustained release, 
swellable and bioadhesive gastro rententive drug delivery system for ofloxacin 
using polymers like psyllium husk, HPMC K100 M by wet granulation method.  
Evaluation studies were conducted and invitro release studies followed Higuchi 
kinetics and drug release mechanism was found to be of anomalous or non-fickian 
type.  The bio adhesive property of developed formulation was found to be 
significant in combination as compared to HPMC K100 M and psyllium husk 
alone.  The evaluation studies were compared with marketed formulation. 
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CHAPTER - 3 
AIM OF WORK 
Drug resistance enforces high dose administration of antibiotics, often generating 
intolerable toxicity, development of new antibiotics, and requests for significant 
economic, labor, and time investments. The main drawbacks for conventional 
antimicrobial agents are the development of multiple drug resistance and adverse side 
effects. Several classes of antimicrobial nanoparticles (NPs) and nanosized carriers for 
antibiotics delivery have proven their effectiveness for treating infectious diseases, 
including antibiotics resistant ones, in vitro as well as in animal models. 
  Cefuroxime axetil is a second generation cephalosporin antibiotic generally used 
for lower and upper respiratory tract infections, genitor-urinary tract infections, skin and 
soft tissue infections.  It is a prodrug that gets converted into cefuroxime after oral 
absorption. The main site of absorption of cefuroxime axetil is in the stomach. The 
marketed preparation has very poor oral bioavailability (25% - 30%) and is variable with 
presence or absence of food. The main side effects of cefuroxime axetil are 
gastrointestinal disturbances including nausea, vomiting, diarrhoea. 
 The main aim of this study is to formulate and evaluate mucoadhesive tablets of 
cefuroxime axetil loaded Solid lipid nanoparticles, for reducing the drug resistance, 
improving the bioavailability, dose reduction, controlled release of drug and also to target 
the drug at its specific site of absorption (Stomach). Solid lipid nanoparticles are 
formulated using various lipids [compritol ATO 888, glyceryl mono stearate (GMS), 
glyceryl mono oleate(GMO), stearic acid, palmitic acid] at different concentrations. 
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Pluronic F68 is used as surfactant/stabilizer and soya lecithin is used as co surfactant to 
increase the solubility of drug in lipid. The best formulation is selected and lyophilized to 
dry powder form. Mucoadhesive tablets are prepared from the lyophilized SLN using 
suitable mucoadhesive polymers (carbopol, HPMC K15) by direct compression method. 
Further characterization for the finished formulation is carried out. 
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PLAN OF WORK 
1. STANDARDIZATION OF CEFUROXIME AXETIL: 
a. Preparation of 0.07N HCl buffer 
b. Determination of λmax & preparation of calibration curve 
 
2. COMPATIBILITY STUDIES OF DRUG AND EXCIPIENTS: 
a. Fourier Transform Infrared spectroscopic studies (FT-IR) 
 
3. FORMULATION OF CEFUROXIME AXETIL LOADED SOLID LIPID 
NANOPARTICLES: 
Solid lipid nanoparticles of cefuroxime axetil are prepared by using 
various lipids at different concentrations by hot homogenization followed with 
ultrasonication technique. 
 
4. CHARACTERIZATION OF CEFUROXIME AXETIL LOADED SOLID 
LIPID NANOPARTICLES: 
a. Determination of drug content 
b. Determination of drug entrapment efficiency 
c. Particle size & zeta potential 
d. In vitro release studies 
e. Kinetics of drug release 
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5. SELECTION AND EVALUATION OF BEST FORMULATION: 
a. Solubility studies 
b. Microbiological assay 
c. Lyophilization of best formulation 
d. X- ray diffraction studies  
e. Morphology of SLN by scanning electron microscopy (SEM) technique 
f. Statistical analysis 
 
6. COMPRESSION OF LYOPHILIZED SLN LOADED WITH 
CEFUROXIME AXETIL INTO MUCOADHESIVE TABLETS: 
 Mucoadhesive tablets are compressed, using suitable mucoadhesive 
polymers, by direct compression method. 
 
7. CHARACTERIZATION OF MUCOADHESIVE TABLETS OF 
LYOPHILIZED SLN LOADED WITH CEFUROXIME AXETIL: 
 
a. Precompression evaluation of powder blend: 
i. Estimation of drug content of lyophilized SLN 
ii. Angle of repose 
iii. Bulk density 
iv. Tapped density 
v. Carr’s index 
vi. Hausner’s ratio 
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b. Post compression evaluation studies: 
i. Drug content of fabricated mucoadhesive tablets 
ii. Thickness & diameter 
iii. Hardness 
iv. Weight variation 
v. Friability test 
vi. Fourier Transform Infrared spectroscopic studies (FT-IR) 
vii. Determination of swelling index 
viii. Invitro release studies 
ix. Invitro release kinetics 
x. In vitro mucoadhesive strength determination 
xi. Determination of in vitro residence time  
xii. Ex vivo stomach permeability studies 
xiii. In vivo gastroretentive time in rabbit stomach 
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CHAPTER - 5 
MATERIALS 
S.No. INGREDIENTS SUPPLIERS 
1 Cefuroxime Axetil 
Gift sample obtained from Steril - gene 
Life Sciences Pvt Ltd. 
2 Compritol ATO 888 Orchid Pharma, Chennai. 
3 Glyceryl monosterate Central Drug House (P) Ltd. 
4 Glyceryl monooleate Otto Chemicals, Mumbai. 
5 Palmitic acid Central Drug House (P) Ltd., New Delhi. 
6 Stearic acid Central Drug House (P) Ltd., New Delhi. 
7 Pluronic F68 
Gift sample obtained from Madras 
Pharmaceuticals. 
8 Soyalecithin Otto Kemi. 
9 Methanol Universal Scientific Suppliers, Madurai. 
10 Chloroform 
Spectrum Reagents and Chemicals, 
Cochin. 
11 Carbopol 934 
Gift sample obtained from Madras 
Pharmaceuticals. 
12 HPMC K15M 
Gift sample obtained from Madras 
Pharmaceuticals. 
13 Magnesium Stearate Nice Chemicals (P) Ltd., Kerala. 
14 Talc Nice Chemicals (P) Ltd., Kerala. 
15 Conc. Hydrochloric acid 
Spectrum Reagents and Chemicals, 
Cochin. 
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EQUIPMENTS 
S.No. EQUIPMENTS DISTRIBUTORS 
1.  Rotary Flash Evaporator Super fit rotary flash evaporator 
2.  Ultra Sonicator Vibronic’s Ultrasonic processor 
3.  Centrifugator Eppendorf Centrifuge 5417 R 
4.  Mechanical stirrer Scientific industries 
5.  Electronic Balance A&D Company, Japan 
6.  Magnetic Stirrer MC Dalal & co 
7.  
Single Punch Tablet Compression 
Machine 
Cadmach Machinery Co. Pvt., 
Ahmadabad. 
8.  Disintegration Apparatus Rolex, India. 
9.  
Digital  Tablet Dissolution Test 
Apparatus 
Disso 2000, Lab India, 
Mumbai. 
10.  Friability Test  Apparatus 
Indian Equipment Corporation, 
Mumbai. 
11.  
Tablets Hardness Tester( 
Monsanto) 
Praveen Enterprises, 
Bangalore. 
12.  Vernier  Caliper Linker, Mumbai. 
13.  UV Visible Spectrophotometer UV Pharma Spec 1700, Shimadzu 
14.  Stability chamber Inlab equipments. 
15.  Rotary shaker Secor, India. 
16.  Scanning electron microscope Hitachi X650, Tokyo, Japan 
17.  Particle size analyser Malvern Instrument, U.K. 
18.  FT-IR Shimadzu, Japan. 
19.  Differential Scanning Calorimetry DSC Q 200, Mumbai. 
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CHAPTER - 6 
DRUG PROFILE 
 
Cefuroxime axetil 
 
 Cefuroxime axetil is a β lactam antibiotic belonging to 2nd generation 
cephalosporin antibiotic and is active against β lactamase producing strains.  
STRUCTURAL FORMULA: 
               
 
EMPIRICAL FORMULA: 
C16H16N4O8S 
CHEMICAL NAME: 
(6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2 
(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic 
acid 
DESCRIPTION:
 
Nature                  :  White powder. 
Solubility             :   Freely soluble in, methanol and acetone, and  
                                slightly soluble in water and dehydrated alcohol. 
    Melting point       :  135.5°C 
Molecular weight :  424.4 
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MECHANISM OF ACTION: 
 Cefuroxime axetil is a 2nd generation cephalosporin antibiotic which acts by 
binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell 
wall; it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is 
then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is 
possible that cefuroxime interferes with an autolysin inhibitor 
PHARMACOKINETICS: 
Absorption:  
 Following oral administration of cefuroxime axetil, the drug is absorbed from 
the GI tract as the 1-(acetyloxy)ethyl ester and rapidly hydrolyzed to cefuroxime.  
 Oral bioavailability is 37-52 % 
Distribution:  
50 % bound to plasma proteins 
Metabolism:  
 No metabolism after hydrolysis from cefuroxime axetil to cefuroxime. 
Elimination: 
 Mean plasma half-life is 1.2-1.6 hours 
 Excreted unchanged principally in urine. 
Therapeutic indicatons: 
        For many bacterial infections such as bronchitis, sinusitis, tonsillitis, ear 
infections, skin infections, gonorrhea, and urinary tract infections. 
Dose 
 500-1000 mg per day 
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Side effects: 
 Gastro intestinal disturbances such as, vomiting, diarrhoea, nausea. 
Drug interactions:  
 Probenacid reduces the renal clearance of cefuroxime. 
 Diuretics increases possible risk of nephrotoxicity. 
Precautions: 
 Should not be given to patients with ahistory of GI disease especially colitis. 
Contra-indications: 
 Known hypersensitivity to cefuoxime or other cephalosporins. 
Brand names: 
 Ceftin 
 Cefurax 
 Elobact 
 Kefurox 
 Oraxim 
 Sharox 
 Supacef 
 Zinacef 
 Zinnat 
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CHAPTER - 7 
EXCIPIENTS PROFILE 
GLYCERYL MONOSTEARATE 
Synonym:
 
           Glyceryl stearate, Monostearin 
Structure: 
 
Chemical name:
 
 3-Stearoyloxy-1,2-propanediol; Glyceryl stearate; Alpha-Monostearin; 
Monostearin; Octadecanoic acid, 2,3-dihydroxypropyl ester; Glycerin 1-monostearate; 
Glycerin 1-stearate; Glycerol alpha-monostearate; Glyceryl 1-monostearate; Stearic 
acid alpha-monoglyceride; Stearic acid 1-monoglyceride; 1-Glyceryl stearate; 1-
Monostearin; 1-Monostearoylglycerol; 1,2,3-Propanetriol 1-octadecanoyl ester. 
Empirical formula: 
          CH3 (CH2)16COOCH2CHOHCH2OH 
Molecular weight: 
 358.56 
Functional category: 
          Emulsifying agent 
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Description: 
          White or cream colored waxy solid. 
Properties:
  
          Physical state  : white powder 
          Melting point  : 63 - 68
 o
C  
          Boiling point  : > 100
 o
C 
          Solubility in water : soluble in hot water 
          Solvent solubility : soluble in methanol and chloroform mixture 
          HLB value  : 5.0 
Stability and storage conditions: 
It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from light. 
Safety: 
It is generally regarded as an essentially non-toxic and non-irritant material at 
the levels employed as an excipients. 
Handling precautions: 
Keep away from heat and ignition.  
Regulatory status: 
Induced in the FDA inactive ingredients and recognized by GRAS status.  
(Handbook of Pharmaceuticals Excipients, 2009, 831-824) 
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GLYCERYL BEHENATE 
Synonyms:
  
Compritol 888 ATO; 2,3-dihydroxypropyl docosanoate; docosanoic acid, 
glyceryl monobehenate, 1,2,3-Propanetriol docosanoate.
 
Structure: 
 
Empirical formula: 
C3H8O3
.
x(C22H44O2) 
Molecular weight: 
414.66 
Functional category: 
Coating agent 
Tablet binder 
Tablet and capsule lubricant 
Description: 
Fine white powder or hard waxy mass with a faint odor. 
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Properties:
 
 
Physical state          :   Fine white powder
 
Melting point          :   65–77ºC 
Boiling point           :   306 ºC 
Solubility                 : Soluble, when heated, in chloroform and dichloromethane. 
Practically insoluble in ethanol(95%), hexane, mineral oil and 
water. 
HLB value               :         12 
Stability and storage conditions: 
It should be stored in a tight container, at a temperature less than 358C. 
Safety: 
It is generally regarded as a relatively nonirritant and nontoxic material. 
Handling precautions: 
It emits acrid smoke and irritating fumes when heated to decomposition. 
Regulatory status: 
Included in the FDA Inactive Ingredients Guide(capsules and tablets). 
(www.sciencelab.com, www.parchem.com, Handbook of Pharmaceuticals Excipients, 
2009, 819-824.) 
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GLYCERYL MONOOLEATE 
Synonym: 
Glyceryl monooleate, monoolein 
Structure: 
 
Chemical name: 
3-Stearoyloxy-1,2-propanediol; Glyceryl stearate; Alpha-Monostearin; 
Monostearin; Octadecanoic acid, 2,3-dihydroxypropyl ester; Glycerin 1-monostearate; 
Glycerin 1-stearate; Glycerol alpha-monostearate; Glyceryl 1-monostearate; Stearic 
acid alpha-monoglyceride; Stearic acid 1-monoglyceride; 1-Glyceryl stearate; 1-
Monostearin; 1-Monostearoylglycerol; 1,2,3-Propanetriol 1-octadecanoyl ester 
Empirical formula: 
CH3 (CH2)16COOCH2CHOHCH2OH 
Molecular weight: 
 358.56 
Functional category: 
Emulsifying agent 
Description: 
 White or cream colored waxy solid. 
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Properties: 
Physical state  : soft solid waxy 
 Melting point  :  40
 o
C  
 Boiling point  : > 100
 o
C 
 Solubility in water : soluble in hot water 
 Solvent solubility : soluble in methanol and chloroform mixture 
 HLB value  : 5.0 
Stability and storage conditions: 
 It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from light. 
Safety: 
 It is generally regarded as an essentially non-toxic and non-irritant material at 
the levels employed as an excipients. 
Handling precautions: 
Keep away from heat and sources of ignition. Empty containers pose a fire 
risk, evaporate the residue under a fume hood. Ground all equipment containing 
material. Do not breathe dust. (www.sciencelab.com, www.parchem.com,) 
 
STEARIC ACID 
Synonyms: 
          Cetylacetic acid; stereophonic acid; Tegostearic. 
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Structure: 
           
Chemical name: 
          Octadecanoic acid  
Empirical formula: 
          C18H36O2 
Molecular weight: 
          284.47 
Functional category: 
         Emulsifying agent  
         Solubilizing agent 
         Tablet and capsule lubricant 
Description: 
          It is a hard, white or faintly yellow-colored, crystalline solid or a white or 
yellowish white powder.  
Properties: 
          Physical state          :     Crystalline solid/white or yellowish powder. 
          Melting point          :          554°C 
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          Boiling point           :         383°C 
          Solubility                :          Freely soluble in benzene, carbon tetrachloride, 
                                                     chloroform, and ether; soluble in ethanol (95%),                     
         hexane and propylene glycol; practically insoluble in                                                                                                                                                                                                                                                                                        
                                           water.                                                         
 HLB value            :          15 
Stability and storage conditions: 
          It is a stable material; an antioxidant may also be added to it. The bulk material 
should be stored in a well-closed container in a cool and dry place. 
Safety: 
          It is generally regarded as a nontoxic and nonirritant material. However, 
consumption of excessive amounts may be harmful. 
Handling precautions: 
          Stearic acid dust may be irritant to skin, eyes, and mucous membranes. Eye 
protection, gloves, and a dust respirator are recommended. Stearic acid is 
combustible. 
Regulatory status: 
          Included in the FDA Inactive Ingredients Guide (sublingual tablets; oral 
capsules,  
solutions, suspensions, and tablets; topical and vaginal preparations).  
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PALMITIC ACID 
Synonyms: 
 Acidum palmiticum; cetylic acid; n-hexadecoic acid; hexadecylic acid; 
Structure: 
           
Chemical name: 
 Hexadecanoic acid 
Empirical formula: 
 C16H32O2 
Molecular weight: 
 256.42 
Functional category: 
 Emulsifying agent  
 Skin penetrant 
 Tablet and capsule lubricant 
Description: 
 Palmitic acid occurs as white crystalline scales with a slight characteristic odor 
and taste. 
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Properties: 
          Physical state          :     White crystalline scales  
          Melting point          :          64 °C 
          Boiling point           :         352 °C 
          Solubility                 :         Soluble in ethanol (95%); practically insoluble in   
                                                      water. 
           HLB value               :         15 
Stability and storage conditions: 
 The bulk material should be stored in a well-closed container in a cool and dry 
place.  
Safety: 
 Palmitic acid is used in oral and topical pharmaceutical formulations and is 
generally regarded as nontoxic and nonirritant at the levels employed as an excipient. 
However, palmitic acid is reported to be an eye and skin irritant at high levels and is 
poisonous by intravenous administration. 
Handling precautions: 
 Observe normal precautions appropriate to the circumstances and quantity of 
material handled. When palmitic acid is heated to decomposition, carbon dioxide and 
carbon monoxide are formed. 
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Regulatory status: 
GRAS listed. Included in the FDA Inactive Ingredients Database (oral tablets). 
Included in nonparenteral medicines licensed in the UK. 
 
POLOXAMER 188  
Synonym: 
Lutrol F 68, Pluronic F 68 
Structure: 
 
Chemical name: 
Polyethylene-Polypropylene Glycol 
Empirical formula: 
HO(C2H4O)a(C3H6O)b(C2H4O)aH 
Molecular weight: 
8400.00 
Functional category: 
 Emulsifying agent 
 Sensitize drug resistant cancers to chemotherapy 
Description: 
White to off white granules 
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Properties: 
 Physical state  : white powder 
 Solubility in water : soluble in water 
 Solvent solubility : soluble in methanol and chloroform mixture 
 HLB value  : 29.0 
Biological effects of poloxamer: 
Originally thought to be inert carrier molecules work led by Kabanov has 
recently shown that some of these polymers have a very real effect on biological 
systems independently of the drug they are transporting. The poloxamers have been 
shown to incorporate into cellular membranes affecting the microviscosity of the 
membranes. 
Stability and storage conditions: 
It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from light. 
Safety: 
It is generally regarded as an essentially non-toxic and non-irritant material at 
the levels employed as an excipients. 
Handling precautions: 
Keep away from heat and sources of ignition. 
 
SOYA LECITHIN 
Synonym: 
Lecithin, soy lecithin 
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Structure: 
 
Chemical name: 
Polyethylene-Polypropylene Glycol 
Empirical formula: 
HO(C2H4O)a(C3H6O)b(C2H4O)aH 
Molecular weight: 
8400.00 
Functional category: 
 Emulsifying agent 
 Sensitize drug resistant cancers to chemotherapy 
Description: 
Light brown to brown liquid 
Properties: 
 Physical state  : Brown liquid 
 Solubility in water : soluble in water 
 Solvent solubility : soluble in methanol and chloroform mixture 
 HLB value  : 15.0 
Stability and storage conditions: 
It is stable if stored at the temperature of 2-8ºC. Product looses its 
potency/performance above 45ºC. No hazardous polymerization occurs. 
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Safety: 
It is generally regarded as an essentially non-toxic and non-irritant material at 
the levels employed as an excipients. 
Handling precautions: 
Keep away from heat and light. 
 
CHAPTER - 8 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL PROTOCOL 
CHAPTER – 8             EXPERIMENTAL PROTOCOL 
MUCOADHESIVE TABLETS OF SLN LOADED WITH DRUG Page 62 
 
CHAPTER - 8 
EXPERIMENTAL PROTOCOL 
1) STANDARDIZATION OF CEFUROXIME AXETIL: (Indian 
Pharmacopoeia 2010) 
a. Preparation of 0.07N HCl buffer: 
    Measure 6.93 ml of hydrochloric acid and gradually dissolve it in 
specified amount of distilled water with continuous stirring and make this 
solution up to 1000 ml using distilled water to prepare 0.07N HCl buffer 
solution. 
b. Determination of λmax & preparation of calibration curve: 
The standard stock solution of Cefuroxime axetil is prepared by 
dissolving 100 mg of drug in 5 ml methanol and diluted with 0.07N HCl 
buffer solution up to 100 ml. From the above stock solution, drug having 
different concentrations of 5, 10, 15, 20 and 25g /ml is prepared using 
0.07N HCl buffer solution with appropriate dilution. 
The 10 ug/ml solution is scanned in UV spectrophotometer to find 
the  max and the absorbance of the samples is measured at max (281nm). 
A graph is plotted by taking concentration in X-axis and absorbance in Y-
axis to obtain the standard curve. 
The standard curve prepared is used to estimate drug content, 
entrapment efficiency and percentage drug release. 
2) COMPATIBILITY STUDIES FOR DRUG AND EXCIPIENTS: 
Compatibility studies are carried out to confirm there are no 
interactions existing between the drug and excipients. It gives information 
needed for selection of excipients with the drug for the formulation of 
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nanosuspension. Infrared spectrophotometry technique is used to check the 
compatibility studies between lipids (compritol ATO 888, glyceryl 
monostearate, glyceryl monooleate, stearic acid & palmitic acid) and drug. 
a. Fourier Transform Infrared Spectroscopic studies (FT-IR): 
 IR studies are carried out to find whether there are interactions between 
pure drug, lipids, surfactants and its physical mixture by KBr pellet technique 
using FTIR spectrophotometer (shimadzu, RX 1, Japan). The IR spectrum of 
the physical mixture is then compared with the spectrum of pure drug 
(cefuroxime axetil) to assess the compatibility of the excipients and drug. The 
scanning range is 450-4000 cm
-1 
and the resolution is 4cm
-1
.                 
            (De Pintu Kumar et al., 2012) 
3) FORMULATION OF CEFUROXIME AXETIL LOADED SOLID LIPID 
NANOPARTICLES: 
Cefuroxime axetil loaded solid lipid nanoparticle is prepared by hot 
homogenization method followed by ultrasonication using different lipids at 
different concentrations [1%, 2%, 4%, 6%, 8% and 10%]. 
In hot homogenization method, the solid lipid and soya lecithin are 
dissolved in a mixture of chloroform and methanol in ratio of 1:1, to which 
drug is added. Now this mixture is taken in a rotary flash evaporator and all 
the organic solvents are completely removed. The resulting residue is melted 
approximately 5 – 10°C above the melting point of the lipid. A 2% aqueous 
surfactant solution of 40ml is prepared and is heated to the same temperature 
of the lipid phase. Now the hot aqueous surfactant solution is added to the 
lipid phase. Homogenization is carried out at 2000 rpm by using mechanical 
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stirrer for 1 hr. Temperature is maintained 5 – 10°C above the melting point of 
the lipid to prevent lipid recrystalization.  
After homogenization is finished, the obtained coarse emulsion is 
allowed to cool to room temperature, while stirring at 400 rpm for 30 minutes. 
The dispersion is then ultrasonicated using a probe sonicator processor for 10 
minutes.             (Priyanka & Abdul Hasan Sathali .A et al., 2012) 
4) CHARACTERIZATION OF CEFUROXIME AXETIL LOADED SOLID 
LIPID NANOPARTICLES: 
The formulated cefuroxime axetil loaded solid lipid nanoparticles are 
characterized for their drug content, entrapment efficiency, particle size, 
polydispersity index, zeta potential, in vitro drug release and kinetics of drug 
release. 
a. Determination of Physicochemical properties: 
The formulated SLNs are to characterize for their physicochemical 
properties such as color, odor and stability after centrifugation over 2000 rpm 
for 30 minutes. 
b. Determination of drug content: 
The total drug content of the SLN formulations is determined by 
spectrophotometric analysis. One milligram equivalent of cefuroxime axetil 
loaded  SLN is dissolved in (1 ml) of methanol and the volume is made up to 
100 ml by using 0.07N HCl buffer solution  to make 10 µg/ ml concentration. 
The absorbance is measured at 281 nm (λ max) using UV spectrophotometer 
(Shimadzu UV-1700 pharma spec, Japan). From the absorbance, drug content 
is calculated. 
 Sample absorbance 
Drug content    =        __________________      x 100 
Standard absorbance 
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c. Determination of drug entrapment efficiency: 
 The entrapment efficiency (EE) is the ratio of amount of drug 
incorporated into the SLNs to the total drug content. The entrapment 
efficiency of cefuroxime axetil loaded SLNs is directly determined by the 
centrifugation method. 1ml of SLN is taken in a centrifuge tube and the 
nanoparticles are separated in a high speed cooling centrifuge (Eppendorf 
Centrifuge 5417 R, Germany) at 14,000 rpm for 90 min at 4°C. Then the 
supernatant liquid is made up to desired volume with 0.07N HCl buffer 
solution to measure the absorbance of free drug at 281nm by using UV 
Spectrophotometer, (Shimadzu UV-1700 pharma spec, Japan) to estimate the 
unentrapped drug for the calculation of % EE. 
The percentage entrapment efficiency (%EE) is calculated by 
following formula: 
Total amount of drug taken - Unentrapped drug  
% EE   =    _________________________________________   x 100 
Total amount of drug taken               
 
(Yitao Wang et al., 2012, Nisha & Abdul Hasan Sathali A et al., 2013) 
d. Particle size and zeta potential: 
Particle size and zeta potential of drug loaded SLN dispersion with 
best entrapment efficiency is done by photon correlation spectroscopy (PCS) 
using a Malvern Zetasizer 3000 Nano ZS (Malvern instruments, UK) at 25°C. 
Prior to measurements all samples are diluted using ultra purified water to 
yield a suitable scattering intensity.      
           (E. B. Souto et al., 2011, Yamasai Madhusudan Rao et al., 2012) 
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e. In vitro release studies: 
In vitro drug release study of cefuroxime axetil from SLN formulations 
is determined by using dialysis bag diffusion method using 0.07N HCl buffer 
solution as dissolution medium.  
The dialysis bags are soaked in distilled water for 24 hrs before use. 
SLN equivalent to 1 mg of cefuroxime axetil is placed inside the dialysis bag 
and sealed at both ends with threads. The dialysis bag is immersed in receptor 
compartment containing 100 ml of 0.07N HCl buffer solution in 250 ml 
beaker maintained at 37°C ± 1°C and magnetically stirred at 100 rpm. 
Samples are withdrawn at predetermined time intervals of 30 min for first 2 
hrs and every 60 min for 10 hrs. Sink condition is maintained by replacing 
with fresh buffer solution after each sample withdrawal. The content of 
cefuroxime axetil in the samples is determined by using UV 
spectrophotometer (Shimadzu UV-1700 pharma spec, Japan) at 281 nm.
 (Kaushik M et al., 2012, Priyanka K, Abdul Hasan Sathali A et al., 
2012, Lakshmi Sirisha Kotikalapud et al., 2012) 
f. Kinetics of drug release: 
In order to understand the release kinetics of a drug, the results of in 
vitro drug release studies of nanoparticles were fit to various kinetic equations 
such as zero order (cumulative % release vs. time), first order (log % drug 
remaining vs. time), and Higuchi’s model (cumulative % drug release vs. 
square root of time). Values of r
2
 and k were calculated for the linear curve 
obtained by regression analysis of the above plots. The exact mechanism of 
drug release was determined by the Korsemeyer–Peppas model (log drug 
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release vs. log time). (R. N. Marreto et al., 2011, Kesavan Bhaskar Reddy et 
al., 2011) 
5) SELECTION AND EVALUATION OF BEST FORMULATION: 
The best formulation selection is based on the results obtained from 
particle size, zeta potential, entrapment efficiency, in vitro release studies and 
kinetics of drug release. 
a. Solubility studies: 
The solubility of the pure drug is compared with the solubility of best 
formulation. An approximately(10 mg) equivalent of pure drug and 
cefuroxime axetil loaded solid lipid nanoparticles are introduced in 25 ml 
stoppered standard conical flask containing 10 ml distilled water. The sealed 
flask is agitated on a rotary shaker for 24 hr. An aliquot is withdrawn and 
filtered and the filtrate is suitably diluted and analysed in UV 
spectrophotometer (Shimadzu UV-1700 pharma spec, Japan).  
    (Nisha. N & Abdul Hasan Sathali A et al., 2013) 
b. Microbiological assay: 
Microbiological activity of drug loaded SLNs is evaluated by 
determination of bacteria colony forming units after incubation of 1% 
suspension of S. aureus bacteria in MRS medium at 30
0
 for 24hrs with drug 
loaded SLNs. 
c. Lyophilization of the best formulation: 
The nanoparticles are lyophilized using a programmable freeze-dryer 
(Shin PVTFD10R, Shinil Lab, Korea). Cryoprotectant is added to the SLN 
dispersion before freezing. Slow freezing is carried out on the shelves in the 
freeze dryer (shelf temp.−40º C). The samples are lyophilized for 24 h from 
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−40º C to 25º C at an increasing rate of 5ºC/h. Lyophilized products are 
reconstituted by sonication. 
d. X- ray diffraction studies: 
PXRD studies are performed in order to indentify the crystallinity 
behavior of the SLN. (Yaping Li, PhD et al., 2011, Lakshmi Sirisha 
Kotikalapudi et al., 2012) 
e. Morphology of SLN by scanning electron microscopy (SEM) 
technique: 
Scanning electron microscopy is an excellent tool for physical 
observation of morphological features of particle both initially and degradation 
process. It is helpful to examine particle shape and surface characteristics such 
as surface area and bulk density. The formulations are poured in a circular 
aluminum stubs using double adhesive tape, and coated with gold in HUS – 
5GB vaccum evaporator and observed in Hitachi S – 3000N SEM at an 
acceleration voltage of 10 Kv and a magnification of 5000X. (Hassan M. 
Ghonaim et al., 2013, Jithan Aukunuru et al., 2010) 
f. Statistical analysis  
Statistical analysis for the determination of differences in permeability 
profiles of cefuroxime axetil loaded SLNs and cefuroxime axetil pure drug 
solution was assessed by the use of Student’s t-test (Graph pad Instat Version 
3.0 software). Statistical probability (p) values less than 0.05 were considered 
significantly different                                               (R. N. Marreto et al., 2011) 
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6) COMPRESSION OF LYOPHILIZED SLN LOADED WITH 
CEFUROXIME AXETIL INTO MUCOADHESIVE TABLETS: 
Controlled release mucoadhesive matrix tablets of lyophilized SLN 
loaded with cefuroxime axetil are formulated by direct compression 
technology. Lyophilized drug loaded SLN and the polymers (carbopol 934 & 
HPMC K15M) in the ratio of 1:1.5 and the other excipients are screened 
through 40 mesh sieve. All materials are accurately weighed and mixed 
intimately for 15 minutes. The directly compressible mixture are compressed 
using single stroke tablet punching machine fitted with 12 mm flat faced 
punch. Before compression, the surface of die and punch are lubricated with 
magnesium stearate. (Vitaliy V. Khutoryanskiy et al., 2012, Yadav V.D. 2013 
et al., 2011) 
7) CHARACTERIZATION OF MUCOADHESIVE TABLETS OF 
LYOPHILIZED SLN LOADED WITH CEFUROXIME AXETIL: 
a. Precompression evaluation of powder blend: 
i. Estimation of drug content of lyophilized SLN: 
Approximately weighed quantity of 100 mg equivalent of cefuroxime 
axetil is taken and transferred into a 100 ml volumetric flask. It is dissolved in 
methanol and made up to the volume with 0.07N HCl buffer. Subsequently the 
solution in volumetric flask is filtered and suitable dilutions are made and 
analyzed at λmax using UV-Visible spectrophotometer (Shimadzu UV-1700, 
pharma spec, Japan). The drug content of each sample is estimated from 
standard curve of cefuroxime axetil using 0.07N HCl buffer.    
       (A. S. Gudigennavar et.al., 2013) 
   Sample absorbance 
         Drug content =                                            x 100 
   Standard absorbance 
  
CHAPTER – 8             EXPERIMENTAL PROTOCOL 
MUCOADHESIVE TABLETS OF SLN LOADED WITH DRUG Page 70 
 
ii. Angle of Repose: 
Angle of repose is defined as the maximum angle possible between the 
surface of a pile of the powder and the horizontal plane. In this method, the 
powder is allowed to flow through the funnel fixed to a stand at definite height 
(h). The angle of repose is then calculated by measuring the height and radius 
of the heap of granules formed. (Aulton M.E., 2002 and Satyabrata Bhanja 
et.al., 2013) 
Tan θ = h/r       
θ = tan-1 (h/r) 
 Where, 
 θ = Angle of repose 
 h = Height of the heap    
 r = radius of the heap 
The relationship between the angle of repose and powder flow is given as, 
Angle of repose Powder flow 
    <250 Excellent 
25-300 Good 
30-400 Passable 
         >400 Very poor 
 
iii. Bulk density (gm /ml)   : 
Bulk density is the ratio between given mass of powder and its bulk 
volume. Bulk density measurements are carried by placing fixed weight of 
powder in graduated cylinder and volume occupied is measured and initial 
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bulk density (gm/ml) is calculated. It is expressed in gm/ml. Bulk density is 
calculated by using following formula,  (Rao G. Umamaheshwara et al., 2012) 
 
Weight of the powder   W 
    Bulk Density =      =   
 
Bulk volume of powder   V 
iv.  Tapped density (gm/ml): 
A known quantity of sample is transferred to a graduated cylinder and 
placed on tapped density apparatus and operated for a fixed number of taps 
(100). It is the ratio of weight of sample to tapped volume.     
        (Rao G. Umamaheshwara et.al., 2012) 
           Weight of the powder            W 
Tapped Density =        _____________________      =     ____   
             
 
   Tapped volume of powder            Vf 
v. Carr’s index: 
  It indicates powder flow properties. It is expressed in percentage and is 
give 
                        Dt - Db 
        I = ------------ ×100 
               Dt 
Where, Dt is the tapped density of the powder 
             Db  is the bulk density of the powder.(Vinod Kombath Ravindran et al., 2012) 
% Compressibility Flow ability 
5 – 12 Excellent 
12 – 16 Good 
18 – 21 Fair Passable 
23 – 35 Poor 
33 – 38 Very Poor 
< 40 Very Very Poor 
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vi. Hausner ratio: 
Hausner ratio is an indirect index of ease of powder flow. It is calculated 
by the following formula.  
                                       Dt 
 Hausner ratio   =        
                                         Db 
 Where, 
  Dt is the tapped density. 
   Db is the bulk density.  
 Lower Hausner ratio (<1.25) indicates better flow properties than higher ones 
(>1.25).                (Vinod Kombath Ravindran et al., 2012) 
b. Post compression evaluation studies: 
i. Drug content of fabricated mucoadhesive tablets: 
Approximately weighed quantity of 100 mg equivalent of cefuroxime 
axetil is taken and transferred into a 100 ml volumetric flask. It is dissolved in 
methanol and made up to the volume with 0.1N Hydrochloric acid.  
Subsequently the solution   in volumetric flask is filtered and suitable dilutions 
are made and analyzed at λmax using UV-Visible spectrophotometer (Shimadzu 
UV-1700, pharma spec, Japan). The drug content of each sample is estimated 
from standard curve of Clozapine using 0.07N HCl buffer.    
       (A. S. Gudigennavar et.al., 2013) 
   Sample absorbance 
         Drug content =                                                 x 100 
   Standard absorbance 
ii.Thickness & Diameter: 
  Three tablets are randomly selected from each formulation and 
thickness and diameter are measured individually by vernier caliper. It is 
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expressed in millimeter (mm) and average is calculated.   
              (D. Krishnarajan et.al., 2013) 
iii. Hardness: 
Tablet requires a certain amount of hardness and resistance to friability 
to withstand mechanical shakes of handling in manufacture, packing and 
shipping. The hardness of the tablets is determined using Monsanto hardness 
tester.  It is expressed in Kg/cm
2
. Three tablets are randomly selected from 
each formulation and hardness of the tablets is determined. The results are 
expressed in average value.    (Akant Priya Singla et. al., 2010) 
iv. Weight variation: 
Twenty tablets are randomly selected from each formulation and 
average is determined. Then individual tablet is weighed and individual is 
compared with average weight. The tablet passes the IP test if not more than 2 
tablets are outside the percentage limits and if no tablet differs by more than 2 
times the percentage limit.         (Indian Pharmacopoeia 1996, Page no: 736) 
 
Average weight 
Maximum % difference 
allowed 
130 mg or less ± 10% 
130 mg to 324 mg ± 7.5% 
More than 324 mg ± 5% 
 
v. Friability test: 
The friability of tablets is determined using Roche Friabilator. Twenty 
tablets are selected from each batch. The tablets are initially weighed (initial 
weight) and transferred into Friabilator. The Friabilator is rotated at 25 rpm for 
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4 minutes, after which the tablets are removed.  Loose dust is removed from 
the tablets as before and the tablets are weighed again (final weight). 
The percentage friability is then calculated by, 
   Initial weight – Final weight  
                    F   =                                                            × 100 
  Final weight 
% Friability of tablets less than 1% is considered acceptable.  
  (Akant Priya Singla et. al., 2010, Goswami Dhruba Sankar et al., 2011) 
vi. Fourier Transform Infrared spectroscopic studies (FT-IR): 
 Infrared spectrometry of the SLN formulation is carried out to 
find out the interactions between the drug and excipients used. 
vii. Determination of swelling index: 
Swelling of tablet due to the excipients particles involves the 
absorption of a liquid resulting in an increase in weight and volume. Liquid 
uptake by the particle may be due to saturation of capillary spaces within the 
particles or hydration of macromolecule. The liquid enters the particles 
through pores and bind to large molecule, breaking the hydrogen bond and 
resulting in the swelling of particle. The extent of swelling can be measured in 
terms of % weight gain by the tablet. In each formulation batch one tablet is 
weighed and placed in a Petri plate containing 25ml of 0.07N HCl buffer. 
After an hour interval of time the tablet is removed from petri plate, and 
excess of buffer is removed by using filter paper.  The same procedure is 
repeated up to 12 hours.     (Vitaliy V. Khutoryanskiy et.al., 2012).  
Swelling index is calculated by using the following formula.               
Swelling index   =   (W2- W1)/W1 x 100 
Where, 
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W1- Initial weight of the tablet, 
W2 – hydrated weight of the tablet. 
viii. In vitro  release studies: 
In vitro release studies are performed by using USP type II Paddle 
dissolution apparatus. 900 ml of freshly prepared 0.07N HCl buffer is used as 
dissolution medium. Temperature is maintained at 37° C ± 1° C.  Samples 
(5ml) are withdrawn at regular intervals of 30 minutes and the same volume of 
fresh dissolution medium is replaced after every withdrawal. The withdrawn 
samples are analyzed by UV- visible spectrophotometer at λ max. The studies 
are done in triplicate. (Akant Priya Singla et. al., 2010). 
ix. In vitro  release   kinetics: 
In controlled or sustained release formulations the three most 
important rate controlling mechanisms are, 
 Diffusion 
 Swelling and 
 Erosion 
The In vitro release profiles obtained from the mucoadhesive tablets 
are fitted to zero order, first order, Higuchi, Hixson Crowell, Korsemeyer & 
Peppas model kinetics, to find out the mechanism of drug release. 
Release Kinetics Model Equation 
Zero Order Qt = Q0 + K0 t 
First Order In Qt = In Q0 + K0 t 
Hixson-Crowell Q0
1/3 – Qt1/3 + K t 
Higuchi Q = KH. t
1/2 
Korsmeyer – Peppas Mt / M0 = a.tn 
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Fitness of release profiles to linear equations is assessed by comparing 
the coefficients of     determination (r) values. For cylinder type of systems, 
n< 0.45  : Classical Fickian diffusion 
n=0.45 to 0.89            : Anomalous Non Fickian transport i.e. coupled                                                                                            
diffusion in the hydrated matrix and  polymer 
relaxation (Indicators of  both phenomenon) 
n=0.89                         : Case II relaxational release transport - Zero  
order release(Polymer relaxation or swelling 
controlled systems)                                                                                                                                                     
n> 0.8   : Super Case II transport. 
        (Inderbir Singh et. al., 2011) 
x. In vitro mucoadhesive  strength  determination: 
Bioadhesive strength of the mucoadhesive tablets is measured on 
modified physical balance. A modified physical balance is used for 
determining the ex vivo mucoadhesive strength of prepared mucoadhesive 
tablets. Fresh sheep stomach mucosa is obtained from a local slaughterhouse.  
Sheep stomach mucosa is tied to the glass petri dish, which is filled with 
0.07N HCl buffer so that it just touched the mucosal surface. The tablet is 
placed on the stomach mucosa. The preload of 5 gm is placed on the tablet and 
the balance is kept in this position for 5 minutes. Then weight of 5 gm is 
removed from the right hand pan, which is loaded along with the tablet over 
the mucosa.  Then water is added slowly to the right hand pan until the tablet 
is detached from the mucosal surface.  (A. S. Gudigennavar et.al., 2013) 
      Mucoadhesive strength =    Weight of the water to detach the tablet 
        from  the mucosal surface (gm) 
          Mucoahesive strength (gm) x 9.81 kg (1N) 
       Force of Adhesion (N) =                                                                                                 
1000 
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 Force of adhesion (N) 
         Bond strength (N/m
2
) = 
Surface area of the tablet (m
2
) 
 
xi. Determination of in vitro residence  time: 
In vitro residence time for tablets is determined using USP 
disintegration apparatus. The disintegration medium composes of 800 ml of 
0.07N HCl buffer and temperature is maintained at 37°C ± 2˚C. A segment of 
sheep stomach mucosa about 3 cm in length is glutted to glass slide and 
mucoadhesive tablet is placed on to the wet sheep stomach mucosa. The glass 
slide vertically attached to disintegration apparatus is completely immersed in 
0.07N HCl buffer. The time taken for the tablet to detach from sheep gastric 
mucosa is recorded as the mucoadhesion time.     
           (Rao G. Umamaheswara et al., 2012) 
xii. Ex vivo stomach permeability studies: 
This study is performed after approval by the Institutional Animal 
Ethical Committee using male Wistar rat. Rat stomach mucosa is used to 
determine the drug permeation profile. Rats fasting for 18 – 20 hours are 
anaesthetized by some ether sprinkled to a piece of cotton wool in a glass 
container equipped with a lid. After making a midline incision in the abdomen, 
stomach is separated and is washed with 0.07N HCl buffer to remove any 
remaining gastric contents. The separated stomach tissue is incised to suitable 
size similar to the size used for Franz Diffusion cell. A modified Franz 
Diffusion cell is used for permeability studies, it consist of one donor 
compartment and a receptor compartment. The receptor compartment is filled 
with 54 ml of pH 1.2 phosphate buffer simulating the blood circulation and the 
donor compartment is filled with 5 ml of 0.07N HCl buffer simulating gastric 
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content. Temperature is maintained at 37
0 
± 1
0
C. The separated stomach 
epithelium was mounted between the two chambers and stomach epithelium 
was allowed to stabilize.  After stabilization of stomach epithelium, the 
mucoadhesive tablet is adhered on stomach epithelium. This system was 
placed on a thermostatic cum magnetic stirrer to generate stirring in the 
receptor compartment.  Periodically, samples are withdrawn and same volume 
fresh medium is replaced.  The aliquots are analyzed spectrophotometrically at 
281nm.       (A. S. Gudigennavar et al., 2013) 
xiii. In vivo  gastroretentive time  in  rabbit stomach: 
The clearance has been obtained from the institutional ethical board 
(Institutional Animal Ethical Committee, Madurai Medical College, Madurai) 
for performing in vivo x-ray studies in rabbits. It is carried out to evaluate the 
mucoadhesive property of the formulated (best formulation) mucoadhesive 
tablets. For this study, mucoadhesive tablets containing barium sulphate (as X-
ray opaque material) is used (instead of cefuroxime axetil). The tablet is 
administered orally to rabbit along with 30 ml of 5% dextrose solution by 
using stomach tube (No.12 French catheter) and 20ml syringes.  X-ray 
photographs are taken at different time intervals (0, 2, 4, 6, 8 and 10 hr) and 
observed for the position of the tablet      
    (Aashima Hooda et al., 2012, A. S. Gudigennavar et al., 2013) 
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CHAPTER - 9 
RESULTS AND DISCUSSION 
1) STANDARDIZATION OF CEFUROXIME AXETIL: 
a. Preparation of 0.07N HCl buffer: 
 The calibration medium of 0.07N hydrochloric acid buffer was prepared as per 
Indian Pharmacopoeia., 2010. 
b. Determination of λmax & Preparation of calibration curve: 
 The absorption maximum (λmax) of cefuroxime axetil was estimated by using 
UV spectrophotometer. It was done by scanning the drug solution (10µg/ml) in 
between 200-400 nm region. The obtained spectrum showed that the absorption 
maximum (λmax) at 281 nm. The absorbance spectrum was shown in figure-1A. 
 The standard calibration curve of cefuroxime axetil was prepared by using 
0.07N HCl buffer. The absorbance was measured at λmax of 281 nm. Good linearity 
was observed with the plot. The „r2‟ value was found to be 0.99982 as shown in table-
1, which was very nearer to „1‟ and hence obeyed “Beer-Lambert” law within the 
concentration range of 5-25 µg/ml. The calibration plot of cefuroxime axetil was 
shown in figure-1B. 
 
2) COMPATIBILITY STUDIES OF DRUG AND EXCIPIENTS: 
a. Fourier Transform Infrared Spectroscopic studies (FT-IR): 
 The IR Spectra of pure drug, lipidic excipients were shown in the figure-3A-
3J. The spectrum was studied at 4000 cm
-1
 – 400 cm1. The spectrum of pure drug 
shows crystalline nature with sharp bands (shown below in table) indicating 
crystallinity. 
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IR interpretation of cefuroxime axetil 
S.NO FUNCTIONAL GROUPS 
OBTAINED WAVE 
NUMBER cm
-1 
1 C-N Stretching 1329 
2 C-S Stretching 755 
3 C=O in β-lactam 1733 
4 C=N Stretching 1527 
5 C-O Stretching in Ester 1249 
6 C=O Stretching in Ester 1757 
7 C=C Stretching (Aromatic) 1558 
8 OCH3 group 1680 
   
In the physical mixture of all the formulations as shown in figure 3K-3O, the 
peaks of cefuroxime axetil shown above was retained indicating that there were no 
interaction between drug and excipients. 
 
3) FORMULATION OF CEFUROXIME AXETIL LOADED SOLID LIPID 
NANOPARTICLES: 
 The composition of the formulation was shown in table-2. All the 
formulations were spontaneously formed when the aqueous phase containing 
surfactant was added drop wise to the stirred melted lipid along with co-surfactant at 
the same temperature with or without cefuroxime axetil, resulting in a colloidal 
suspension. The prepared SLN dispersion was found to be uniform and homogenous 
in appearance. 
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4) CHARACTERIZATION OF CEFUROXIME AXETIL LOADED SOLID 
LIPID NANOPARTICLES: 
a. Determination of Physicochemical properties: 
           The SLN dispersion was milky white in appearance, odorless, and fluid 
in nature. It was stable and did not show sedimentation even after centrifugation 
(2000 rpm for 30 minutes). 
b. Determination of drug content: 
  The percentage drug content for all the formulations (SLN1-SLN30) were 
shown in the table-3. The drug content was found in the range of 98.48% - 96.97%, 
indicating uniform distribution of drug in formulations. 
c. Determination of drug entrapment efficiency: 
 The results of EE were shown in the tables 3A–3E and figure-2. The EE of 
the formulations SLN1-SLN6 (glyceryl behenate (compritol ATO 888) at different 
ratios (1%, 2%, 4%, 6%, 8% & 10%) showed 49.88 ± 0.88% to 68.09 ± 0.68%; the 
formulation SLN7-SLN12 (glyceryl monostearate at different ratios (1%, 2%, 4%, 
6%, 8% & 10%)  showed 45.16 ± 1.52 to 62.88 ± 0.67%; the formulation SLN13-
SLN18 (glyceryl monooleate at different ratios (1%, 2%, 4%, 6%, 8% & 10%) 
showed  27.52 ± 0.94% to 45.07 ± 1.22%; the formulation SLN19-SLN24 stearic acid 
at different ratios (1%, 2%, 4%, 6%, 8% & 10%)  showed 22.79 ± 2.02% to 37.34 ± 
1.25%; the formulation SLN25-SLN30 (palmitic acid at different ratios (1%, 2%, 4%, 
6%, 8% & 10%)  showed 18.28 ± 2.00% to 33.91 ± 1.86%. The influence of 
surfactant and lipid concentrations was discussed below. 
 From the above results it showed that the EE of the formulations increase with 
increase of lipid concentration. This was because that when the lipid concentration 
increases there would be more lipid to entrap the drug molecules. Among the various 
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lipids used compritol showed highest drug entrapment, because of the presence of 
long chain fatty alcohols. Because of the long chain fatty alcohols, the lipid could 
accommodate more drug molecules in it comparing to the other lipids. The order of 
EE of the lipids was given as, 
Compritol>Glyceryl monostearate>Glyceryl monoleate>Stearic acid>Palmitic 
acid 
 The effect of surfactant on the EE was also studied. Generally when the 
particle size of the formulation was reduced cohesive forces exists between them, 
which would lead to particle aggregation. Therefore in order to overcome this hurdle 
the use of surfactant was applied. Pluronic F68 was selected as the outer phase 
stabilizer, which get coated on the outer surface of the nano particles, thereby 
preventing their aggregation (Abdul Hasan Sathali A et al., 2012). A 2% 
concentration of the surfactant was applied for an effective stabilization, because upto 
certain extend the effect of the surfactant increases and beyond that there were no 
effective results            (Lakshmi Sirisha Kotikalapudi et al,. 2012). 
When the drug was not evenly distributed in the lipid phase, the proper entrapment of 
the drug molecules in the lipid matrix may not be achieved, so the use of a co-
surfactant was needed. Here soya lecithin was used as co-surfactant/solubilizer in the 
formulations, which solubilizes/disperse the drug in the lipid matrix evenly. 
              (Lakshmi Sirisha Kotikalapudi et al,. 2012) 
d. Particle size  & Zeta potential: 
 Nanoparticles were characterized by mean particle diameter and their 
distribution. The particle size of the formulations with best EE was shown in table-5 
and their distribution curves were shown in figure 10A-10E. 
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Formulation SLN6 prepared using lipid-compritol ATO 888 containing 
showed mean particle size of 512.6nm. 
Formulation SLN12 prepared using lipid-glyceryl monostearate showed mean 
particle size of 148.nm. 
Formulation SLN18 prepared using lipid-glyceryl monooleate showed mean 
particle size of 104.3nm. 
Formulation SLN24 prepared using lipid-stearic acid showed mean particle 
size of 319.5nm. 
Formulation SLN30 prepared using lipid-Palmitic acid showed mean particle 
size of 467.2nm. 
Surfactant plays an important role in particle size of the formulations. 
Surfactant was used for stearic stabilization of the formulated nano particles, 
preventing them from aggregating to form micro particles. To produce an optimum 
particle size for the formulations, pluronic F68 at 2% concentration was used which 
was kept constant for all the formulations. 
The various lipids and their various concentrations also contribute to the 
particle size. Here the melting point of the lipids plays an important role. The higher 
the melting point of the lipid the higher would be its particle size, lower the melting 
point lower would be its particle size(Maria Antonietta Casadei et al,. 2011). The 
order of melting point of the lipids used were given as, 
Glyceryl monooleate<Glyceryl monostearate<Stearic acid<palmitic 
acid<Compritol 
 The concentrations of the lipids also influence the particle size. An increase in 
particle size was observed when the concentrations of lipids were increased. This was 
because when the concentrations of the lipids were increased the amount of surfactant 
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used could not completely emulsify the lipids and also the surfactant could not give 
enough stearic stabilization. But since the particle size of the highest concentrations of 
the different lipids were not more than 515 nm, the formulations with best EE ie, 
highest lipid concentrations were selected. 
Polydispersity index (PDI): 
The PDI for the formulations as shown in table-5 and figure 11A-11E is 
smaller than 0.5, which indicates a relative homogenous dispersion. Polydispersity 
index indicates particle size distribution, which ranges from 0 to 1. Theoretically, 
monodisperse populations indicates PI = 0. However, PI < 0.2 was considered as 
narrow distribution and those greater than 0.5 indicate high homogenicity (Krutika 
Sawant et., 2013). 
 The zeta potential of the formulations with best EE was evaluated, which was 
shown in table-6 and figure 11A-11E. Zeta potential of formulations SLN6, SLN12, 
SLN18, SLN24 & SLN30 showed negative zeta potential of-9.42mV, -22.9mV, -16.5, 
-10.5 & -15.9 resectively. 
Zeta potential of about -25mV allows an ideal stabilization of nanoparticles 
because the repulsive forces prevent aggregation upon ageing. All nanoparticles 
showed a high negative residual charge due to chemical nature of the lipid matrix 
(stearic acid/oleic acid/behenic acid) and surfactant used (Krutica Sawant et al., 2013) 
e. In vitro release studies: 
The invitro drug release of the formulations showed a biphasic release pattern 
ie, both first and zero order drug release as shown in table 7A-7E and figure 4A-4E. 
Burst effect 
From the obtained drug release data, a burst release was seen in all the 
formulations. Higher lipid ratios led to lower burst release in the first two hours 
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(23.19±1.21, 28.35±0.73, 29.79±1.53, 33.40±0.86, 36.17±0.60) showing lower release 
from the lipid due to higher EE and lower lipid concentrations led to higher burst 
release (33.25±1.71, 40.17±0.49, 43.63±2.19, 46.76±1.94, 50.05±1.48) showing 
higher release due to lower EE. 
This might be due to the presence of unentraped drug on the outer surface of 
the nanoparticles. This shows that the formulated SLNs were in “Drug Enriched Shell 
Model”. The faster release was due to the presence of larger surface area, as the 
particles were in nano size. The burst release decreases with an increase in lipid 
concentration, because there would be more amount of lipid to entrap the drug 
molecules. 
The burst release might be also useful for producing immediate action. 
Sustained effect 
 Followed by the burst release for 2 hours, SLN formulations showed sustained 
effect for 12 hours. 
The release for SLN1-6 (compritol ATO 888) was 68.80±1.55 – 53.31±1.13 
The release for SLN7-12 (glyceryl monostearate) was 71.83±1.08 – 57.28±1.02 
The release for SLN13-18 (glyceryl monooleate) was 87.37±1.33 – 69.90±1.67 
The release for SLN19 - 24 (stearic acid) was 92.48±2.21 –77.53±1.53 
The release for SLN25 - 30 (palmitic acid) was 94.01±1.41 – 80.90±0.91 
Among the various lipids used, compritol ATO 888 showed more sustained 
release than the glyceryl monooleate and glyceryl monostearate due to its longer 
carbon chain length than the other two lipids. Moreover GMO and GMS, were lipids 
with lower melting point when compared to compritol ATO 888, can produce a 
controlled release from SLN. This is due to the presence of solid solution throughout 
the particle combined with the slow diffusion of drug from the lipid matrix. 
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The order of drug release from the three lipids as follows: 
Glyceryl monooleate>Glyceryl monostearate>Stearic acid>palmitic 
acid>Compritol. 
From the results it was concluded that higher lipid concentration and longer 
carbon chain length of fatty acids sustained the drug release from SLNs. 
f. Kinetics of drug release: 
The data obtained from the drug release studies were plotted in various kinetic 
models such as, 
 Cumulative percentage drug release Vs time (zero order rate kinetics) 
 Log cumulative percentage drug remaining Vs time (first order rate kinetics) 
 Cumulative percentage drug release Vs square root of time (Higuchi classical 
diffusion model) 
 Cube root of percentage drug remaining Vs time (Hixon Crowell erosion 
equation). 
 Log cumulative percentage drug release Vs log time (Korsmeyer Peppas 
exponential equation) 
The r
2
 values and k values were shown in table 8A-8E and figures 5A-9E 
Among the models tested, the drug release profile of all formulations were 
best fitted with first order with r
2
 values ranging from 0.973-0.988 and Higuchi model 
with r
2
 values ranging from 0.979 -  0.992. From the results higuchi release kinetics 
showed purely diffusion controlled. 
The „n‟ values obtained from Hixon Crowell were within 0.4-0.8 which indicated 
that the drug release mechanism followed Non-Fickian diffusion (Abdul Hasan 
Sathali .A and Priyanka .K., 2012) 
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5) SELECTION AND EVALUATION OF BEST FORMULATION 
Based on entrapment efficiency and in vitro release 
 Based on the entrapment efficiency, the formulations containing compritol 
ATO 888 as lipid showed higher entrapment. This might be due to longer chain length 
of the lipid. Due to high entrapment, drug release from SLNs was sustained. So 
according to this release profile formulation SLN6 (compritol ATO 888-10%) was 
selected as one of the best formulations. 
       Based on particle size 
 The optimized formulations SLN12 & SLN18 (GMS-10% & GMO-10%) with 
lowest particle size was selected for further evaluation studies. 
Selected best 
Formulation 
code 
Entrapment 
efficiency (%)   
± SD 
Drug release 
(%)  ± SD 
Particle size 
(nm) 
SLN6 68.09 ± 0.68 53.31 ± 1.13 
512.6 
SLN12 62.88 ± 0.67 57.28 ± 1.02 
148.0 
SLN18 45.07 ± 1.22 69.90 ± 1.69 
104.3 
 
a. Solubility studies: 
Solubility results were showed in table-9 and figure-12. The solubility of 
cefuroxime axetil in distilled water was found to be 0.241 mg/ml at room temperature 
which increased significantly to 0.871 ± 0.002 mg/ml (SLN18-104.3nm), 0.730 ±  
0.003 mg/ml (SLN12- 148 nm), 0.508 ± 0.004 mg/ml (SLN6- 512.6 nm)  after 
formulating as solid lipid nanoparticle. This was indicating that drastic increase in 
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surface area, resulting from particle size reduction, greatly enhanced the solubility of 
the drug (Abdul Hasan Sathali .A and Nisha .N,. 2012). 
b. Microbiological assay: 
 The microbiological action of the formulated SLNs was shown below.  
S. No. Composition Zone of Inhibition 
1 Pure drug    - 1 16 
2 GMO          - 2 19 
3 GMS           - 3 21 
4 Compritol   - 4 17 
5 Standard      - S 16 
 The zone of inhibition of SLNs was found to be much higher than that of 
pure drug (cefuroxime axetil) and standard () in a 24 hours study. This was achieved 
because of their nano size (Compritol-512.6nm, GMS-148nm, and GMO-104.3nm). 
And also the SLNs showed continuous antimicrobial action throughout 24 hours, due 
to their controlled action. 
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c. Lyophilization of best formulation: 
Dry amorphous formulations (F1, F2 & F3) were obtained after lyophilization 
process. 
d. X-ray diffraction studies: 
The x-ray diffraction studies showed amorphous state of drug in formulations as 
shown in figure-22A, 22B, 22C & 22D. 
e. Morphology of SLN by Scanning electron microscopy (SEM) technique: 
From the obtained SEM images, the SLNs showed a spherical shape and also 
an almost smooth appearance as shown in the figure-21, 22 & 23 
6) COMPRESSION OF LYOPILIZED SLN LOADED WITH 
CEFUROXIME AXETIL INTO MUCOADHESIVE TABLETS: 
 The individually weighed powder blends of lyophilized SLN along with other 
excipients mentioned in table-10 were compressed in to tablets in a single punch 
tablet compressing machine. Each tablet contains 125mg eqiuivalent of cefuroxime 
axetil lyophilized SLN. Carbapol 934 and HPMC K15M were used as mucoadhesive 
polymers, magnesium stearate and talc as lubricants. The prepared mucoadhesive 
tablets were white in colour and round in shape.       
(Margret Chandira et al., 2009) 
 
7. CHARACTERIZATION OF MUCOADHESIVE TABLETS OF 
LYOPHILIZED SLN LOADED WITH CEFUROXIME AXETIL: 
a. Precompression evaluation of powder blend: 
i. Estimation of drug content: 
The drug content of the formulations F1, F2 & F3 were found to be 90.93%, 
97.73% & 94.33%, showing an uniform distribution of drug. 
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ii. Angle of Repose  
Angle of repose for the formulations F1, F2 & F3 were 28.66°, 29.28° & 
27.39° and the powder blends of all formulations shows good flow properties. The 
results of angle of repose of all formulations were shown in table-11 & figure-13. 
iii. Bulk density ( gm /ml)    
 The bulk density for the formulations F1, F2 & F3 were 0.544g/cm
3
, 0.555 
g/cm
3
 & 0.554 g/cm
3
. The results indicated that the powder blends of all twenty 
formulations have good flow properties. The results were summarized in table -11 & 
figure-14. 
iv. Tapped density (gm/ml)  
 Tapped density for the formulations F1, F2 & F3 were 0.664g/cm
3
, 0.676 
g/cm
3 
& 0.624 g/cm
3
, indicating the presence of smaller particles occupying the voids 
between the the bigger particles. The results of all the formulations were summarized 
in table-11 & figure-16. 
v. Carr’s index: 
             The carr‟s index of the formulations F1, F2 & F3 were found to be 18.06%, 
17.89% & 11.16% which indicated that the powder blend was fairly passable. The 
results of all the formulations were summarized in table-11. 
vi. Hausner’s ratio: 
The Hausner ratio of the formulations F1, F2 & F3 were found to be 1.21, 1.21 & 
1.12. Since a very low Hausner ratio (<1.25) was obtained the formulations showed 
better property. The results of all the formulations were summarized in table-11. 
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b. Post compression evaluation studies: 
i. Drug content of fabricated mucoadhesive tablets: 
The drug content of the formulations F1, F2 & F3 as given in table-12 were 
119.68mg (95.75%), 121.45mg (97.16%) & 120.75mg (96.60%) which shows an 
uniform drug content in the formulations and also it complies with USP limit (not less 
than 90% & not more than 110%) 
ii. Thickness & Diameter: 
The thickness for the formulations F1, F2 & F3 was 6mm, 5mm & 6mm. The 
results were summarized in Table-12. The diameter of all the formulations was 
12mm. the results indicated an uniform particle size distribution and no deformities. 
iii. Hardness: 
The hardness for the formulations F1, F2 & F3 was 7kg/cm
3
, 6 kg/cm
3
 & 
7kg/cm
3
. The results indicated that the tablets of all formulations have good hardness, 
which in turn protects them from mechanical damage. The results were summarized in 
Table-12. 
iv. Weight variation: 
The weight of all the formulations   ranges from 799.5mg ± 40, 800.2mg ± 40 
& 800.7mg ± 40 and were tabulated in Table-12. The formulations F1, F2 & F3 
tablets passed weight variation test and the weight variation was within the standard 
pharmacopoeial limits of ± 5% of the weight. The results indicated that all tablets of 
each formulation were of uniform weight. 
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v. Friability test: 
Friability of the formulations F1, F2 & F3 was 0.43%, 0.33 % & 0.28%. The 
results indicated that the friability for tablets of all formulations were below 1% (I.P. 
limit 1%) and hence exhibit good mechanical resistance.  The results were shown in 
Table-12. 
vi. Fourier Transform Infrared spectroscopic studies (FT-IR): 
From the obtained FT-IR interaction studies as shown in figures 3P-3R, the 
peaks obtained from pure cefuroxime axetil (1329cm
-1
, 755 cm
-1
, 1733 cm
-1
 & 1529 
cm
-1
) were also found in the final formulations as well, which indicated that there 
were no interactions between drug and excipients. 
vii. Determination of swelling index: 
The swelling index of the formulations F1, F2 & F3 at the 12
th
 hour as given in table-
14 and figure-17 was 215%, 194.23% & 212.51% which shows an optimum swelling 
efficiency due to the presence of hydrophilic polymers (HPMC K15M & Carbopol). 
           (Margret Chandira et al., 2009) 
viii. Invitro release studies: 
The invitro drug release studies of formulations F1, F2 & F3 as give in table-
15 and figure-18 was 67.19%, 65.70% & 68.41%. The controlled release rate was 
achieved because of the hydrophilic polymers, (HPMC K15M & Carbopol) which on 
hydration swells in an controlled manner resulting in controlled release of drug. 
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ix. Invitro release kinetics: 
The r
2
 value of higuchi kinetics for formulations F1, F2 & F3 as given in 
table-16 amd figure 19A-19E, was 0.968, 0.975 & 0.964 which were all less than 1 
indicating pure diffusion process. The n vlue of korsmeyer peppas kinetics were less 
than o.4 indicagin g that the releade follows fickian diffusion ie., drug release by 
diffusion.    (Inderbir Singh et al., 2011) 
x. In vitro mucoadhesive strength determination:   
The invitro mucoadhesive strength of formulations F1, F2 & F3 as given in 
table-13 and figure-16 was 37.01gm, 34.63gm & 37.86gm This bioadhesive strength 
was acheived by the formation of secondary bioadhesion bonds with mucin and 
interpenetration of the polymer chains in the interfacial region, by the hydrophilic 
pllymers.          (Margret Chandira et al., 2009) 
xi. Determination of in vitro residence time :  
The in vitro gastro residence time for formulation F1, F2 & F3 was 10hrs 
28mins, 10hrs 38mins & 10hrs 18mins as given in table-13. This indicates that the 
formulation adheres to the gastric mucosa long enough to deliver the drug efficiently 
for more than 10hours. 
xii. Ex vivo stomach permeability studies: 
From permeation studies, the formulation F1, F2 &F3 as given in table-17 & 
figure-20 showed drug permeation of 90.49%. From this study it was noted that the 
formulation containing lyophilized SLN showed more permeation than that of pure 
drug and mucoadhesive tablets containing plain drug. This might be due to the 
presence of nano particle size. 
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xiii. In vivo gastroretentive time in rabbit stomach: 
From the figure 23A-23F, it was clearly shown that even at the 8
th
 hour the 
tablet still adheres to the mucosal membrane. This was due to the presence of 
mucoadhesive polymers (HPMC K15M & carbopol 934). 
TABLE-1     CALIBRATION OF CEFUROXIME AXETIL USING BUFFER 
0.07N HCl 
S. No CONCENTRATION (μg/ml) ABSORBANCE 
1 5 0.180 ± 0.002 
2 10 0.353 ± 0.006 
3 15 0.535 ± 0.008 
4 20 0.707 ± 0.005 
5 25 0.887 ± 0.002 
            r = 0.99982 
 
 
TABLE-4A    ENTRAPMENT EFFICIENCY OF SLN USING GLYCERYL 
BEHENATE (COMPRITOL) AS LIPID 
S. No LIPID % ENTRAMENT EFFICIENCY % ± SD 
1 1 49.88 ± 0.88 
2 2 53.87 ± 0.36 
3 4 57.62 ± 0.71 
4 6 61.77 ± 1.09 
5 8 66.25 ± 1.04 
6 10 68.09 ± 0.68 
 
n=3* 
 
 
TABLE-4B     ENTRAPMENT EFFICIENCY OF SLN USING GLYCERYL 
MONOSTEARATE AS LIPID 
S. No LIPID % ENTRAMENT EFFICIENCY % ± SD 
1 1 45.16 ± 1.52 
2 2 44.3 ± 2.34 
3 4 50.42 ± 1.62 
4 6 54.18 ± 1.42 
5 8 56.78 ± 2.33 
6 10 62.88 ± 0.67 
 
 
 
TABLE-4C     ENTRAPMENT EFFICIENCY OF SLN USING GLYCERYL 
MONOOLEATE AS LIPID 
S. No LIPID % ENTRAMENT EFFICIENCY % ± SD 
1 1 27.52 ± 0.94 
2 2 29.42 ± 0.81 
3 4 32.29 ± 1.16 
4 6 37.68 ± 0.18 
5 8 40.85 ± 1.32 
6 10 45.07 ± 1.22 
 
n=3* 
 
 
TABLE-4D     ENTRAPMENT EFFICIENCY OF SLN USING STEARIC ACID 
AS LIPID 
S. No LIPID % ENTRAMENT EFFICIENCY % ± SD 
1 1 22.79 ± 2.02 
2 2 27.04 ± 2.31 
3 4 30.57 ± 0.39 
4 6 33.54 ± 1.17 
5 8 35.25 ± 1.56 
6 10 37.34 ± 1.25 
 
 
 
TABLE-4E     ENTRAPMENT EFFICIENCY OF SLN USING PALMITIC 
ACID AS LIPID 
S. No LIPID % 
ENTRAMENT EFFICIENCY % ± 
SD 
1 1 18.28 ± 2.00 
2 2 21.57 ± 1.10 
3 4 24.74 ± 1.09 
4 6 27.41 ± 2.11 
5 8 30.55 ± 0.68 
6 10 33.91 ± 1.86 
 
n=3* 
 
 TABLE-3   DRUG CONTENT 
S. No CODE DRUG CONTENT (mg) ± SD 
1 SLN 1 122.76 ± 0.71 
2 SLN 2 122.27 ± 1.23 
3 SLN 3 123.22 ± 0.71 
4 SLN 4 121.92 ± 0.89 
5 SLN 5 121.09 ± 1.87 
6 SLN 6 121.92 ± 0.73 
7 SLN 7 120.98 ± 1.42 
8 SLN 8 115.07 ± 5.79 
9 SLN 9 118.73 ± 4.95 
10 SLN 10 118.38 ± 5.03 
11 SLN 11 114.60 ± 4.42 
12 SLN 12 121.09 ± 2.32 
13 SLN 13 122.16 ± 1.06 
14 SLN 14 121.92 ± 0.89 
15 SLN 15 122.86 ± 0.93 
16 SLN 16 122.51 ± 1.41 
17 SLN 17 123.33 ± 1.07 
18 SLN 18 120.15 ± 0.74 
19 SLN 19 121.45 ± 1.27 
20 SLN 20 121.18 ± 2.59 
21 SLN 21 121.69 ± 1.08 
22 SLN 22 122.51 ± 1.27 
23 SLN 23 121.69 ± 1.81 
24 SLN 24 122.36 ± 1.51 
25 SLN 25 121.68 ± 2.40 
26 SLN 26 121.80 ± 2.21 
27 SLN 27 122.39 ± 1.59 
28 SLN 28 122.27 ± 1.23 
29 SLN 29 121.21 ± 1.59 
30 SLN 30 121.21 ± 2.13 
n=3* 
TABLE-5     PARTICLE SIZE OF FORMULATIONS WITH BEST ENTRAPMENT 
EFFICIENCY 
CODE LIPID (%) 
MEAN DIAMETER 
(nm) 
PDI 
SLN 6 10 512.6 0.534 
SLN 12 10 148.0 0.230 
SLN 18 10 104.3 0.252 
SLN 24 10 319.5 0.421 
SLN 30 10 467.2 0.395 
  
 
 
 
TABLE-6     ZETA POTENTIAL OF FORMULATIONS WITH BEST ENTRAPMENT 
EFFICIENCY 
S. No CODE ZETA POTENTIAL (mV) 
1 SLN 6 -9.42 
2 SLN 12 -22.9 
3 SLN 18 -16.5 
4 SLN 24 -10.2 
5 SLN 30 -15.9 
TABLE-9     COMPARISON OF SOLUBILITY AMOUNG BEST 
FORMULATIONS 
TIME IN 
HOURS 
SOLUBILITY (mg/ml)  ± SD 
PURE DRUG SLN 6 SLN 12 SLN 18 
24 hours 0.241 ± 0.003 0.508 ± 0.004 0.730 ± 0.003 0.871 ± 0.002 
 n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-10     FORMULA 
INGREEDIENTS 
F1 (SLN6-
Compritol) 
F2 (SLN12-GMS) F3 (SLN18-GMO) 
Lyophilized 
cefuroxime SLNs 
468 mg 468 468 
Carbopol 934 100 mg 100 mg 100 mg 
HPMC K15M 200 mg 200 mg 200 mg 
Talc 16 mg 16 mg 16 mg 
Magnesium 
stearate 
16 mg 16 mg 16 mg 
 
 
Table-11     PRECOMPRESSIONAL EVALUATION   OF   POWER BLEND 
 
CODE 
 
ANGLE 
OF 
REPOSE 
ϴ 
±SD* 
 
BULK 
DENSITY 
( g/ml 
)±SD* 
 
TAPPED 
DENSITY 
(g/ml)±SD* 
DRUG 
CONTENT 
% 
CARR’S 
INDEX 
% 
HAUSNER 
RATIO 
 
F1 28.66 ± 
0.88 
0.544 ± 
0.00 
0.664 ± 
0.003 
90.93 
18.06 ± 
0.42 
1.21 ± 0.005 
 
F2 29.28 ± 
1.32 
0.555 ± 
0.00 
0.676 ± 
0.006 
97.73 
17.89 ± 
0.83 
1.21 ± 0.005 
 
F3 27.39 ± 
1.41 
0.554 ± 
0.04 
0.624 ± 
0.005 
94.33 
11.16 ± 
0.08 
1.12 ± 0.005 
 
n=3*  
 
 Table-12    POST COMPRESSION EVALUATION OF MUCO ADHESIVE 
TABLETS CONTAINING LYOPHILIZED CEFUROXIME AXETIL SLN 
CODE 
HARDNES
S (KG/CM
2
) 
THICK
NESS 
(MM) 
DIAME
TER 
(MM) 
% 
FRIABI
LITY 
(%) 
AVERAGE 
WEIGHT 
(mg) [±5 
%(±40mg)] 
DRUG 
CONTENT 
(mg) 
F1 7 6 12 0.43 799.5 119.68 
F2 6 5 12 0.33 800.2 121.45 
F3 7 6 12 0.28 800.7 120.75 
 
 
Table-13     POST COMPRESSION EVALUATION OF MUCO ADHESIVE 
TABLETS CONTAINING LYOPHILIZED CEFUROXIME AXETIL SLN 
CODE 
 
MUCOADHESIVE 
STRENGTH 
(gm)±SD* 
 
FORCE OF 
ADHESION 
(N)±SD* 
BOND 
STRENGTH 
(N/m
2
) ±SD* 
IN VITRO 
RESIDENCE 
TIME 
(Hrs) 
F1 37.01 ± 1.09 0.362 ± 0.011 0.724 ± 0.014 10hrs 28mins 
F2 34.63 ± 1.11 0.339 ± 0.011 0.678 ± 0.021 10hrs 38mins 
F3 37.86 ± 0.88 0.371 ± 0.008 0.742 ± 0.011 10hrs 18mins 
n=3* 
Table-14     SWELLING INDEX OF MUCOADHESIVE TABLETS 
TIME 
(HOURS) 
F1 (SLN6-
COMPRITOL) 
F2 (SLN12-GMS) F3 (SLN18-GMO) 
1 23.28 ± 0.43 11.18 ± 0.11 25.77 ± 0.58 
2 49.83 ± 0.76 36.51 ± 0.42 41.70 ± 0.66 
3 66.29 ± 0.53 52.73 ± 0.35 58.99 ± 0.49 
4 85.61 ± 0.23 69.20 ± 0.22 76.53 ± 0.72 
5 101.39 ± 0.11 84.80 ± 0.26 93.33 ± 0.64 
6 120.73 ± 0.37 102.00 ± 0.39 110.50 ± 0.53 
7 136.21 ± 0.15 117.30 ± 0.47 127.79 ± 0.61 
8 150.06 ± 0.67 133.84 ± 0.31 144.09 ± 0.43 
9 165.89 ± 0.62 149.43 ± 0.10 163.62 ± 0.63 
10 181.47 ± 0.59 163.66 ± 0.29 179.54 ± 0.88 
11 197.00 ± 0.88 178.38 ± 0.31 196.46 ± 0.75 
12 215.00 ± 0.47 194.23 ± 0.16 212.51 ± 0.70 
 
n=3* 
 
 
 
 
 TABLE-16     INVITRO RELEASE KINETICS 
Formulation 
code 
Zero order First order 
Higuchi 
model 
Korsmeyer 
peppas 
Hixon-Crowell 
 
R
2
 
 
K0 
(h
-1
) 
 
R
2
 
 
K1 
(h
-1
) 
 
R
2
 
 
KH 
(h
-1/2
) 
 
R
2
 
 
n 
 
R
2
 
 
KHC 
(h
-1/3
) 
F 1 
0.869 4.147 0.954 -0.032 16.87 0.968 0.963 0.309 0.934 -0.095 
F 2 0.889 4.147 0.961 -0.031 16.75 0.975 
0.962 
0.330 0.944 -0.093 
F 3 0.861 4.167 0.951 -0.033 0.964 17.01 0.964 0.300 0.929 -0.096 
 
 
 
 Table-15     CUMULATIVE % DRUG RELEASE OF MUCOADHESIVE TABLETS 
TIME 
(HOURS) 
F1 (SLN6-
COMPRITOL) 
F2 (SLN12-GMS) F3 (SLN18-GMO) 
0.5 26.34 ± 0.51 24.23 ± 0.40 27.29 ± 0.20 
1.0 29.05 ± 0.42 26.81 ± 0.42 30.00 ± 0.31 
1.5 31.90 ± 0.42 29.46 ± 0.31 33.26 ± 0.47 
2.0 34.14 ± 0.23 31.56 ± 0.81 35.50 ± 0.31 
3.0 37.81 ± 0.31 35.46 ± 0.05 39.09 ± 0.53 
4.0 41.67 ± 0.23 39.71 ± 0.20 42.96 ±0.20 
5.0 45.27 ± 0.11 43.71 ± 0.11 46.42 ± 0.35 
6.0 48.12 ± 0.11 45.750 ± 0.31 48.73 ± 1.50 
7.0 51.18 ± 0.31 49.14 ± 0.71 52.33 ± 0.40 
8.0 55.11 ±0.31 53.08 ± 0.71 56.13 ± 0.31 
9.0 58.91 ± 0.31 56.84 ± 0.05 60.00 ± 0.42 
10.0 61.63 ± 0.51 59.66 ± 0.61 62.65 ± 0.82 
11.0 65.09 ± 0.23 63.46 ± 0.11 66.17 ± 0.40 
12.0 67.19 ± 0.73 65.70 ± 0.42 68.41 ± 0.61 
 
n=3* 
 
 
 
 
 
 TABLE-17     EX VIVO DRUG PERMEATION STUDIES OF CEFUROXIME 
AXETIL ACROSS RAT STOMACH EPITHELIUM 
TIME 
(HOURS) 
PURE DRUG ±SD 
MUCOADHESIVE 
TABLET LOADED 
WITH FREE DRUG 
±SD 
MUCOADHESIVE 
TABLET LOADED 
WITH LYOPHILIZED 
SLN (±SD) 
0 0 0 0 
0.5 6.13±0.12 6.31±0.54 23.09±0.63 
1 10.20±0.22 8.55±0.23 26.49±0.45 
1.5 15.63±0.76 9.57±0.51 29.88±0.21 
2 19.02±0.55 12.22±0.62 34.63±0.87 
3 23.09±0.54 14.87±0.89 43.45±0.68 
4 27.17±0.11 16.49±0.23 47.53±0.59 
5 28.52±0.88 18.53±0.64 52.99±0.75 
6 35.99±0.23 20.16±0.43 58.42±0.48 
7 38.70±0.55 21.794±0.55 63.77±0.48 
8 40.74±0.34 23.62±0.32 69.40±0.49 
9 43.45±0.19 26.27±0.23 75.47±0.30 
10 47.53±0.45 29.93±0.95 81.53±0.52 
11 50.92±0.57 33.80±0.39 86.58±0.75 
12 53.44±0.34 37.02±0.13 90.49±0.45 
 
n=3* 
 
 
 
 
TABLE-2     FORMULA 
S.NO CODE 
COMPOSITION 
LIPID PERCENTAGE (%) SURFACTANT 
% W/V CO- SURFACTANT 
% W/V 
1 SLN 1 Compritol ATO 888 1 Poloxamer 188 2 Soya lecithin 
2 
2 SLN 2 Compritol ATO 888 2 Poloxamer 188 2 Soya lecithin 
2 
3 SLN 3 Compritol ATO 888 4 Poloxamer 188 2 Soya lecithin 
2 
4 SLN 4 Compritol ATO 888 6 Poloxamer 188 2 Soya lecithin 
2 
5 SLN 5 Compritol ATO 888 8 Poloxamer 188 2 Soya lecithin 
2 
6 SLN 6 Compritol ATO 888 10 Poloxamer 188 2 Soya lecithin 
2 
7 SLN 7 Glyceryl monostearate 1 Poloxamer 188 2 Soya lecithin 
2 
8 SLN 8 Glyceryl monostearate 2 Poloxamer 188 2 Soya lecithin 
2 
9 SLN 9 Glyceryl monostearate 4 Poloxamer 188 2 Soya lecithin 
2 
10 SLN 10 Glyceryl monostearate 6 Poloxamer 188 2 Soya lecithin 
2 
11 SLN 11 Glyceryl monostearate 8 Poloxamer 188 2 Soya lecithin 
2 
12 SLN 12 Glyceryl monostearate 10 Poloxamer 188 2 Soya lecithin 
2 
13 SLN 13 Glyceryl monooleate 1 Poloxamer 188 2 Soya lecithin 
2 
14 SLN 14 Glyceryl monooleate 2 Poloxamer 188 2 Soya lecithin 
2 
15 SLN 15 Glyceryl monooleate 4 Poloxamer 188 2 Soya lecithin 
2 
 S.NO CODE 
COMPOSITION 
LIPID PERCENTAGE (%) SURFACTANT % W/V CO- SURFACTANT 
% W/V 
16 SLN 16 Glyceryl monooleate 6 Poloxamer 188 2 Soya lecithin 2 
17 SLN 17 Glyceryl monooleate 8 Poloxamer 188 2 Soya lecithin 2 
18 SLN 18 Glyceryl monooleate 10 Poloxamer 188 2 Soya lecithin 2 
19 SLN 19 Stearic acid 1 Poloxamer 188 2 Soya lecithin 2 
20 SLN 20 Stearic acid 2 Poloxamer 188 2 Soya lecithin 2 
21 SLN 21 Stearic acid 4 Poloxamer 188 2 Soya lecithin 2 
22 SLN 22 Stearic acid 6 Poloxamer 188 2 Soya lecithin 2 
23 SLN 23 Stearic acid 8 Poloxamer 188 2 Soya lecithin 2 
24 SLN 24 Stearic acid 10 Poloxamer 188 2 Soya lecithin 2 
25 SLN 25 Palmitic acid 1 Poloxamer 188 2 Soya lecithin 2 
26 SLN 26 Palmitic acid 2 Poloxamer 188 2 Soya lecithin 2 
27 SLN 27 Palmitic acid 4 Poloxamer 188 2 Soya lecithin 2 
28 SLN 28 Palmitic acid 6 Poloxamer 188 2 Soya lecithin 2 
29 SLN 29 Palmitic acid 8 Poloxamer 188 2 Soya lecithin 2 
30 SLN 30 Palmitic acid 10 Poloxamer 188 2 Soya lecithin 2 
 
TABLE-7A     COMPARISON OF CUMULATIVE % DRUG RELEASE OF CEFUROXIME AXETIL LOADED SLN 
USING GLYCERYL BEHENATE (COMPRITOL) AS LIPID 
 
TIME(HRS) 
 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
SLN 1 
COMPRITOL 
1% 
SLN 2 
COMPRITOL 
2% 
SLN 3 
COMPRITOL 
4% 
SLN 4  
COMPRITOL 
6% 
SLN 5 
COMPRITOL 
8% 
SLN 6 
COMPRITOL 
10% 
0.5 8.87 ± 1.65 6.98 ± 0.86 11.60 ± 1.01 7.36 ± 1.29 4.44 ± 0.71 2.55 ± 1.23 
1.0 18.44 ± 1.57 16.43 ± 1.00 20.26 ± 1.03 15.49 ± 1.15 13.19 ± 0.59 11.00 ± 1.32 
1.5 26.56 ± 2.02 23.97 ± 1.16 27.83 ± 1.25 21.79 ± 1.15 19.28 ± 0.60 17.44 ± 1.15 
2.0 33.25 ± 1.71 30.54 ± 1.16 33.31 ± 1.21 27.39 ± 1.16 24.76 ± 0.58 23.19 ± 1.21 
3.0 38.78 ± 1.95 36.04 ± 1.31 36.66 ± 1.06 31.82 ± 1.04 29.07 ± 0.61 27.30 ± 1.11 
4.0 43.04 ± 1.81 40.27 ± 1.35 39.76 ± 1.39 35.16 ± 1.20 32.38 ± 0.59 30.68 ± 1.20 
5.0 46.38 ± 1.99 43.68 ± 1.21 42.70 ± 1.40 37.96 ± 1.20 35.06 ± 0.62 32.97 ± 1.06 
6.0 49.67 ± 1.83 47.04 ± 1.21 45.66 ± 1.42 40.69 ± 1.35 37.95 ± 0.63 35.84 ± 1.07 
7.0 53.16 ± 1.70 50.32 ± 0.94 48.55 ± 1.27 43.63 ± 1.37 40.68 ± 0.76 38.74 ± 1.08 
8.0 56.32 ± 1.71 53.45 ± 0.81 51.09 ± 1.25 46.22 ± 1.23 43.52 ± 0.64 41.66 ± 1.09 
9.0 59.31 ± 1.73 56.79 ± 1.01 53.75 ± 1.29 49.02 ± 1.11 46.49 ± 0.65 44.60 ± 1.10 
10.0 62.32 ± 1.76 59.97 ± 0.97 56.42 ± 1.15 51.75 ± 1.12 49.38 ± 0.55 47.39 ± 0.98 
11.0 65.36 ± 1.81 63.08 ± 0.98 59.22 ± 1.16 54.40 ± 0.98 52.11 ± 0.55 50.29 ± 1.12 
12.0 68.80 ± 1.55 66.51 ± 1.27 62.03 ± 1.17 57.18 ± 0.99 55.06 ± 0.78 53.31 ± 1.13 
n=3* 
TABLE-7BCOMPARISON OF CUMULATIVE % DRUG RELEASE OF CEFUROXIME AXETIL LOADED SLN USING 
GLYCERYL MONOSTEARATE AS LIPID 
 
TIME(HRS) 
 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
SLN 7 
GMS  1% 
SLN 8 
GMS  2% 
SLN 9 
GMS  4% 
SLN 10 
GMS  6% 
SLN 11 
GMS  8% 
SLN 12 
GMS  10% 
0.5 16.78 ± 0.71 14.90 ± 0.32 12.54 ± 0.58 10.94 ± 0.43 9.15 ± 1.27 6.51 ± 1.29 
1.0 25.23 ± 0.87 24.36 ± 0.32 21.97 ± 0.75 19.59 ± 0.65 17.59 ± 1.35 15.96 ± 0.57 
1.5 32.85 ± 0.32 32.16 ± 0.57 29.18 ± 0.66 26.50 ± 0.82 24.76 ± 1.48 23.30 ± 0.73 
2.0 40.17 ± 0.49 38.72 ± 0.99 34.86 ± 0.93 31.67 ± 0.92 30.20 ± 1.18 28.35 ± 0.73 
3.0 45.76 ± 0.33 43.16 ± 1.72 38.23 ± 0.84 35.39 ± 1.20 33.81 ± 1.04 32.03 ± 1.02 
4.0 49.33 ± 0.45 46.23 ± 2.16 41.15 ± 0.85 38.38 ± 1.33 36.88 ± 0.91 34.90 ± 1.22 
5.0 52.07 ± 0.45 48.95 ± 2.18 43.91 ± 0.69 41.30 ± 1.35 39.50 ± 1.29 37.69 ± 1.07 
6.0 54.75 ± 0.51 51.97 ± 2.20 46.60 ± 0.70 44.06 ± 1.40 42.34 ± 1.47 40.51 ± 1.1 
7.0 57.35 ± 0.61 54.92 ± 2.22 49.41 ± 0.80 47.04 ± 1.41 45.11 ± 1.32 43.26 ± 1.30 
8.0 60.35 ± 0.60 57.71 ± 2.10 52.24 ± 0.92 49.85 ± 1.27 47.90 ± 1.25 46.13 ± 1.15 
9.0 63.09 ± 0.63 60.71 ± 2.27 55.10 ± 0.98 52.59 ± 1.28 50.43 ± 1.57 48.93 ± 1.07 
10.0 65.95 ± 0.47 63.55 ± 2.14 57.98 ± 1.06 55.35 ± 1.29 53.08 ± 1.74 51.75 ± 1.01 
11.0 68.92 ± 1.07 66.31 ± 2.02 61.07 ± 1.32 58.13 ± 1.03 55.84 ± 1.85 54.60 ± 0.93 
12.0 71.83 ± 1.08 69.28 ± 1.69 64.28 ± 1.52 59.74 ± 1.12 58.72 ± 1.72 57.28 ± 1.02 
n=3* 
TABLE-7C     COMPARISON OF CUMULATIVE % DRUG RELEASE OF CEFUROXIME AXETIL LOADED SLN 
USING GLYCERYL MONOOLEATE AS LIPID 
 
TIME(HRS) 
 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
SLN 13 
GMO  1% 
SLN 14 
GMO  2% 
SLN 15 
GMO  4% 
SLN 16 
GMO  6% 
SLN 17 
GMO  8% 
SLN 18 
GMO  10% 
0.5 19.33 ± 1.72 16.97 ± 1.13 16.97 ± 1.13 16.97 ± 1.13 7.17 ± .099 3.59 ± 1.17 
1.0 28.10 ± 1.85 26.38 ± 1.00 26.38 ± 1.00 26.38 ± 1.00 16.57 ± 1.07 12.77 ± 1.30 
1.5 36.30 ± 1.87 34.84 ± 1.01 34.84 ± 1.01 34.84 ± 1.01 25.13 ± 0.99 21.38 ± 1.32 
2.0 43.63 ± 2.19 41.88 ± 0.19 41.88 ± 0.19 41.88 ± 0.19 33.11 ± 0.61 29.79 ± 1.53 
3.0 50.47 ± 2.04 48.61 ± 0.41 48.61 ± 0.41 48.61 ± 0.41 40.03 ± 0.74 36.59 ± 1.54 
4.0 57.09 ± 1.68 54.83 ± 0.26 54.83 ± 0.26 54.83 ± 0.26 45.23 ± 1.18 41.28 ± 1.67 
5.0 62.35 ± 1.27 60.08 ± 0.46 60.08 ± 0.46 60.08 ± 0.46 48.97 ± 1.32 44.80 ± 1.69 
6.0 66.44 ± 1.45 63.95 ± 1.02 63.95 ± 1.02 63.95 ± 1.02 52.65 ± 1.33 48.62 ± 1.70 
7.0 70.00 ± 1.42 67.49 ± 1.31 67.49 ± 1.31 67.49 ± 1.31 55.97 ± 1.21 52.01 ± 1.84 
8.0 73.59 ± 1.53 70.96 ± 1.04 70.96 ± 1.04 70.96 ± 1.04 59.72 ± 1.21 55.81 ± 1.74 
9.0 77.11 ± 1.55 74.45 ± 0.77 74.45 ± 0.77 74.45 ± 0.77 63.40 ± 1.23 58.88 ± 1.75 
10.0 80.38 ± 1.56 78.07 ± 0.92 78.07 ± 0.92 78.07 ± 0.92 67.10 ± 1.24 62.55 ± 1.77 
11.0 83.95 ± 1.57 81.63 ± 0.92 81.63 ± 0.92 81.63 ± 0.92 70.37 ± 1.39 65.97 ± 1.51 
12.0 87.37 ± 1.33 85.21 ± 0.93 85.21 ± 0.93 85.21 ± 0.93 74.04 ± 1.42 69.90 ± 1.69 
n=3* 
TABLE-7D     COMPARISON OF CUMULATIVE % DRUG RELEASE OF CEFUROXIME AXETIL LOADED SLN 
USING STEARIC ACID AS LIPID 
 
 
TIME(HRS) 
 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
SLN 19 
STEARIC ACID 
1% 
SLN 20 
STEARIC ACID 
2% 
SLN 21 
STEARIC ACID 
4% 
SLN 22 
STEARIC ACID 
6% 
SLN 23 
STEARIC ACID 
8% 
SLN 24 
STEARIC ACID 
10% 
0.5 21.78 ± 1.69 17.35 ± 2.15 13.20 ± 0.71 9.62 ± 1.23 8.68 ± 1.39 7.83 ± 0.71 
1.0 30.66 ± 2.00 26.27 ± 2.06 22.17 ± 0.87 19.29 ± 1.15 18.34 ± 1.15 16.63 ± 0.59 
1.5 38.91 ± 2.04 34.57 ± 1.93 30.52 ± 0.66 28.47 ± 1.09 27.22 ± 1.15 52.21 ± 0.57 
2.0 46.76 ± 1.94 43.04 ± 1.83 38.85 ± 0.73 35.65 ± 1.21 34.20 ± 0.94 33.40 ± 0.86 
3.0 54.78 ± 1.92 50.93 ± 1.96 46.32 ± 0.74 43.09 ± 1.18 41.15 ± 0.32 40.91 ± 0.88 
4.0 61.55 ± 1.93 56.34 ± 1.83 52.26 ± 0.78 48.90 ± 1.33 46.85 ± 0.21 46.13 ± 1.41 
5.0 65.55 ± 1.95 60.95 ± 2.15 56.83 ± 0.47 54.19 ± 1.24 51.18 ± 0.54 50.93 ± 1.10 
6.0 69.40 ± 1.97 64.85 ± 1.86 60.88 ± 0.76 56.89 ± 1.35 54.42 ± 0.27 54.26 ± 0.96 
7.0 73.75 ± 2.14 69.15 ± 2.08 64.86 ± 0.76 60.94 ± 1.27 59.10 ± 0.75 57.52 ± 1.44 
8.0 77.85 ± 1.72 73.03 ± 2.21 68.60 ± 0.77 64.54 ± 1.66 63.16 ± 1.55 60.43 ± 1.61 
9.0 81.23 ± 1.47 77.12 ± 1.77 73.22 ± 0.71 69.59 ± 1.35 68.29 ± 1.36 66.11 ± 1.20 
10.0 84.54 ± 1.49 80.58 ± 1.48 77.03 ± 0.97 73.65 ± 1.36 71.96 ± 0.98 70.42 ± 0.95 
11.0 88.92 ± 1.77 84.17 ± 2.06 80.49 ± 0.65 77.37 ± 1.28 75.66 ± 1.23 73.72 ± 1.59 
12.0 92.48 ± 2.21 87.50 ± 1.93 83.79 ± 0.90 80.17 ± 1.17 78.45 ± 0.81 77.53 ± 1.53 
n=3* 
 TABLE-7E     COMPARISON OF CUMULATIVE % DRUG RELEASE OF CEFUROXIME AXETIL LOADED SLN 
USING PALMITIC ACID AS LIPID 
 
TIME(HRS) 
 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
SLN 25 
PALMITIC ACID  
1% 
SLN 26 
PALMITIC ACID 
2% 
SLN 27 
PALMITIC ACID  
4% 
SLN 28 
PALMITIC ACID  
6% 
SLN 29 
PALMITIC 
ACID  8% 
SLN 30 
PALMITIC ACID 
10% 
0.5 25.55 ± 0.99 24.23 ± 0.58 22.35 ± 0.56 19.05 ± 1.60 16.31 ± 1.81 13.01 ± 0.48 
1.0 34.76 ± 0.85 33.62 ± 0.49 31.15 ± 0.71 27.53 ± 1.94 24.96 ± 1.81 21.44 ± 0.65 
1.5 42.93 ± 1.16 42.06 ± 0.59 39.28 ± 0.57 35.72 ± 1.76 33.50 ± 1.50 29.00 ± 0.43 
2.0 50.05 ± 1.48 48.50 ± 0.76 45.51 ± 0.72 42.96 ± 0.58 40.53 ± 0.86 36.17 ± 0.60 
3.0 56.66 ± 1.06 55.20 ± 0.87 51.80 ± 0.88 35.72 ± 2.21 46.39 ± 1.75 42.56 ± 0.50 
4.0 61.55 ± 0.91 60.83 ± 0.78 58.34 ± 0.88 53.27 ± 2.23 52.69 ± 2.41 49.20 ± 1.13 
5.0 65.73 ± 1.19 64.06 ± 0.75 60.98 ± 0.60 58.41 ± 2.38 58.01 ± 2.22 54.48 ± 1.04 
6.0 70.13 ± 0.93 68.44 ± 0.63 66.28 ± 0.75 65.19 ± 2.12 63.09 ± 1.55 58.97 ± 0.78 
7.0 74.38 ± 1.21 73.15 ± 1.06 71.90 ± 0.63 69.30 ± 1.99 66.90 ± 1.25 62.27 ± 0.69 
8.0 79.61 ± 1.22 78.74 ± 0.97 76.92 ± 0.76 71.66 ± 2.01 69.23 ± 1.26 65.59 ± 0.90 
9.0 83.75 ± 1.23 82.12 ± 0.65 79.72 ± 0.80 75.44 ± 2.21 72.43 ± 1.15 69.61 ± 0.87 
10.0 87.55 ± 1.25 86.38 ± 0.82 83.30 ± 0.81 79.07 ± 1.80 75.94 ± 0.24 73.66 ± 0.65 
11.0 90.72 ± 0.97 89.63 ± 0.67 86.99 ± 0.65 82.64 ± 2.09 80.13 ± 1.07 76.98 ± 0.72 
12.0 94.01 ± 1.41 92.44 ± 0.95 89.59 ± 0.51 86.04 ± 1.68 84.27 ± 1.02 80.90 ± 0.91 
n=3* 
 TABLE-8A     RELEASE KINETICS OF CEFUROXIME AXETIL LOADED SLN USING GLYCERYL BEHENATE 
(COMPRITOL) AS LIPID 
Formulation 
code 
Zero order First order 
Higuchi 
model 
Korsmeyer 
peppas 
Hixon-Crowell 
 
R
2
 
 
K0 
(h
-1
) 
 
R
2
 
 
K1 
(h
-1
) 
 
R
2
 
 
KH 
(h
-1/2
) 
 
R
2
 
 
n 
 
R
2
 
 
KHC 
(h
-1/3
) 
SLN 1 
0.891 4.917 0.973 -0.038 0.979 19.82 0.947 0.566 0.947 -0.110 
SLN 2 0.905 4.852 0.971 -0.035 0.982 19.74 
0.940 
0.615 0.954 -0.106 
SLN 3 0.866 4.174 0.944 -0.029 0.975 16.33 0.957 0.465 0.922 -0.089 
SLN 4 0.897 4.084 0.956 -0.027 0.981 16.45 0.949 0.564 0.939 -0.083 
SLN 5 0.912 4.050 0.962 -0.026 0.981 16.56 0.917 0.662 0.948 -0.081 
SLN 6 0.918 4.006 0.964 -0.025 0.980 16.56 0.879 0.771 0.951 -0.079 
 
 
 TABLE-8B     RELEASE KINETICS OF CEFUROXIME AXETIL LOADED SLN USING GLYCERYL MONOSTEARATE 
AS LIPID 
Formulation 
code 
Zero order First order 
Higuchi 
model 
Korsmeyer 
peppas 
Hixon-Crowell 
 
R
2
 
 
K0 
(h
-1
) 
 
R
2
 
 
K1 
(h
-1
) 
 
R
2
 
 
KH 
(h
-1/2
) 
 
R
2
 
 
n 
 
R
2
 
 
KHC 
(h
-1/3
) 
SLN 7 
0.840 4.699 0.944 -0.038 0.970 18.13 0.970 0.419 0.916 -0.110 
SLN 8 0.847 4.553 0.944 -0.036 0.971 17.60 
0.961 
0.430 0.918 -0.104 
SLN 9 0.862 4.238 0.943 -0.031 0.972 16.46 0.956 0.447 0.921 -0.092 
SLN 10 0.878 4.140 0.949 -0.029 0.979 16.26 0.960 0.476 0.929 -0.088 
SLN 11 0.880 4.049 0.947 -0.027 0.975 16.06 0.949 0.509 0.928 -0.084 
SLN 12 0.890 4.056 0.951 -0.027 0.973 16.30 0.922 0.574 0.934 -0.083 
 
 
 
 TABLE-8C     RELEASE KINETICS OF CEFUROXIME AXETIL LOADED SLN USING GLYCERYL MONOOLEATE 
AS LIPID 
Formulation 
code 
Zero order First order 
Higuchi 
model 
Korsmeyer 
peppas 
Hixon-Crowell 
 
R
2
 
 
K0 
(h
-1
) 
 
R
2
 
 
K1 
(h
-1
) 
 
R
2
 
 
KH 
(h
-1/2
) 
 
R
2
 
 
n 
 
R
2
 
 
KHC 
(h
-1/3
) 
SLN 13 
0.879 6.016 0.986 -0.065 0.988 23.63 0.989 0.455 0.968 -0.168 
SLN 14 0.885 5.917 0.984 -0.064 0.987 23.38 
0.983 
0.477 0.966 -0.159 
SLN 15 0.879 5.776 0.979 -0.055 0.979 23.06 0.966 0.515 0.957 -0.148 
SLN 16 0.909 5.690 0.984 -0.048 0.987 23.16 0.966 0.596 0.968 -0.137 
SLN 17 0.907 5.501 0.979 -0.044 0.982 22.55 0.942 0.647 0.962 -0.127 
SLN 18 0.912 5.332 0.977 -0.040 0.980 22.19 0.900 0.783 0.961 -0.118 
 
 
 TABLE-8D     RELEASE KINETICS OF CEFUROXIME AXETIL LOADED SLN USING STEARIC ACID AS LIPID 
Formulation 
code 
Zero order First order 
Higuchi 
model 
Korsmeyer 
peppas 
Hixon-Crowell 
 
R
2
 
 
K0 
(h
-1
) 
 
R
2
 
 
K1 
(h
-1
) 
 
R
2
 
 
KH 
(h
-1/2
) 
 
R
2
 
 
n 
 
R
2
 
 
KHC 
(h
-1/3
) 
SLN 19 
0.874 6.264 0.978 -0.079 0.988 24.43 0.990 0.437 0.972 -0.191 
SLN 20 0.888 6.130 0.986 -0.066 0.988 24.45 
 0.983 
0.484 0.971 -0.170 
SLN 21 0.904 6.071 0.988 -0.059 0.987 24.29 0.977 0.544 0.974 -0.158 
SLN 22 0.911 5.940 0.986 -0.053 0.987 24.18 0.961 0.603 0.972 -0.147 
SLN 23 0.920 5.871 0.988 -0.051 0.989 23.97 0.959 0.622 0.975 -0.143 
SLN 24 0.917 5.787 0.984 -0.049 0.985 23.74 0.954 0.648 0.971 -0.138 
 
 
 
 TABLE-8E     RELEASE KINETICS OF CEFUROXIME AXETIL LOADED SLN USING PALMITIC ACID AS LIPID 
Formulation 
code 
Zero order First order 
Higuchi 
model 
Korsmeyer 
peppas 
Hixon-Crowell 
 
R
2
 
 
K0 
(h
-1
) 
 
R
2
 
 
K1 
(h
-1
) 
 
R
2
 
 
KH 
(h
-1/2
) 
 
R
2
 
 
n 
 
R
2
 
 
KHC 
(h
-1/3
) 
SLN 25 
0.868 6.189 0.972 -0.085 0.992 23.65 0.993 0.393 0.973 -0.199 
SLN 26 0.873 6.150 0.978 -0.080 0.991 23.60 
0.992 
0.403 0.973 -0.191 
SLN 27 0.884 6.094 0.986 -0.072 0.993 23.61 0.994 0.423 0.974 -0.179 
SLN 28 0.892 5.949 0.987 -0.062 0.992 23.35 0.991 0.455 0.971 -0.163 
SLN 29 0.893 5.870 0.983 -0.058 0.989 23.28 0.985 0.487 0.967 -0.154 
SLN 30 0.912 5.853 0.988 -0.053 0.992 23.58 0.945 0.536 0.974 -0.147 
 
 
FIGURE-1A   DETERMINATION OF λMAX OF CEFUROXIME 
AXETIL 
 
 
FIGURE-1B   CALIBRATIONOF CEFUROXIME AXETIL 
 
 FIGURE-2   ENTRAPMENT EFFICIENCY OF CEFUROXIME 
AXETIL LOADED SLN USING DIFFERENT LIPIDS AT 
DIFFERENT CONCENTRATIONS 
 
 
FIGURE-3A     FT-IR SPECTRA OF CEFUROXIME AXETIL 
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 FIGURE-3B      FT-IR SPECTRA OF GLYCERYL BEHENATE 
(COMPRITOL ATO 888) 
 
 
 
FIGURE-3C     FT-IR SPECTRA OF GLYCERYL 
MONOSTEARATE 
 
 FIGURE-3D     FT-IR SPECTRA OF GLYCERYL MONOOLEATE 
 
 
 
FIGURE-3E     FT-IR SPECTRA OF STEARIC ACID 
 
 
 FIGURE-3F     FT-IR SPECTRA OF PALMITIC ACID 
 
 
 
FIGURE-3G     FT-IR SPECTRA OF POLOXAMER 188 
 
FIGURE-3H     FT-IR SPECTRA OF SOYA LECITHIN 
 
 
 
FIGURE-3I     FT-IR SPECTRA OF CARBOPOL 934 
 
FIGURE-3J     FT-IR SPECTRA OF HPMC K15M 
 
 
FIGURE-3K     FT-IR SPECTRA OF PHYSICAL MIXTURE 
(CEFUROXIME AXETIL + COMPRITOL + HPMC K15M + 
CARBOPOL 934) 
 
 
FIGURE-3L     FT-IR SPECTRA OF PHYSICAL MIXTURE 
(CEFUROXIME AXETIL + GMS + HPMC K15M + CARBOPOL 
934) 
 
 
FIGURE-3M     FT-IR SPECTRA OF PHYSICAL MIXTURE 
(CEFUROXIME AXETIL + GMO + HPMC K15M + CARBOPOL 
934) 
 
FIGURE-3N     FT-IR SPECTRA OF PHYSICAL MIXTURE 
(CEFUROXIME AXETIL + STEARIC ACID + HPMC K15M + 
CARBOPOL 934) 
 
 
FIGURE-3O     FT-IR SPECTRA OF PHYSICAL MIXTURE 
(CEFUROXIME AXETIL + PALMITIC ACID + HPMC K15M + 
CARBOPOL 934) 
 
 
FIGURE-3P     FT-IR SPECTRA OF FINAL FORMULATION-F1 
(CEFUROXIME AXETIL + COMPRITOL + HPMC K15M + 
CARBOPOL 934) 
 
 
 
FIGURE-3Q     FT-IR SPECTRA OF FINAL FORMULATION-F2 
(CEFUROXIME AXETIL + GMS + HPMC K15M + CARBOPOL 
934) 
 
 
 
FIGURE-3R    FT-IR SPECTRA OF FINAL FORMULATION-F3 
(CEFUROXIME AXETIL + GMO + HPMC K15M + CARBOPOL 
934) 
 
 
 
 
 
FIGURE-4A     INVITRO DRUG RELEASE STUDIES OF SLN 
LOADED WITH CEFUROXIME AXETIL USING COMPRITOL 
AS LIPID 
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FIGURE-4B     INVITRO DRUG RELEASE STUDIES OF SLN 
LOADED WITH CEFUROXIME AXETIL USING GLYCERYL 
MONOSTERATE AS LIPID  
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FIGURE-4C     INVITRO DRUG RELEASE STUDIES OF SLN 
LOADED WITH CEFUROXIME AXETIL USING GLYCERYL 
MONOSTERATE AS LIPID 
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FIGURE-4D     INVITRO DRUG RELEASE STUDIES OF SLN 
LOADED WITH CEFUROXIME AXETIL USING STEARIC ACID 
AS LIPID 
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FIGURE-4E     INVITRO DRUG RELEASE STUDIES OF SLN 
LOADED WITH CEFUROXIME AXETIL USING PALMITIC 
ACID AS LIPID  
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RELEASE KINETICS 
FIGURE-5A     FIRST ORDER KINETICS OF SLN USING 
COMPRITOL AS LIPID 
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FIGURE-5B     FIRST ORDER KINETICS OF SLN USING 
GLYCERYL MONOSTEARATE AS LIPID 
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FIGURE-5C     FIRST ORDER KINETICS OF SLN USING 
GLYCERYL MONOOLEATE AS LIPID 
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FIGURE-5D     FIRST ORDER KINETICS OF SLN USING 
STEARIC ACID AS LIPID 
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FIGURE-5E     FIRST ORDER KINETICS OF SLN USING 
PALMITIC ACID AS LIPID 
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FIGURE-6A     ZERO ORDER KINETICS OF SLN USING 
COMPRITOL AS LIPID 
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FIGURE-6B     ZERO ORDER KINETICS OF SLN USING 
GLYCERYL MONOSTEARATE AS LIPID 
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FIGURE-6C     ZERO ORDER KINETICS OF SLN USING 
GLYCERYL MONOOLEATE AS LIPID 
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FIGURE-6D     ZERO ORDER KINETICS OF SLN USING 
STEARIC ACID AS LIPID 
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FIGURE-6E     ZERO ORDER KINETICS OF SLN USING 
PALMITIC ACID AS LIPID 
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FIGURE-7A     HIGUCHI MODEL RELEASE KINETICS OF SLN 
USING COMPRITOL AS LIPID 
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FIGURE-7B     HIGUCHI MODEL RELEASE KINETICS OF SLN 
USING GLYCERYL MONOSTEARATE AS LIPID 
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FIGURE-7C     HIGUCHI MODEL RELEASE KINETICS OF SLN 
USING GLYCERYL MONOOLEATE AS LIPID 
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FIGURE-7D     HIGUCHI MODEL RELEASE KINETICS OF SLN 
USING STEARIC ACID AS LIPID 
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FIGURE-7E     HIGUCHI MODEL RELEASE KINETICS OF SLN 
USING PALMITIC ACID AS LIPID 
0 1 2 3 4
0
20
40
60
80
100
SLN 25
SLN 26
SLN 27
SLN 28
SLN 29
SLN 30
TIME (HOURS)
C
U
M
U
L
A
T
IV
E
 %
 D
R
U
G
 R
E
L
E
A
S
E
 
FIGURE-8A     KORSMEYER PEPPAS MODEL RELEASE 
KINETICS OF SLN USING COMPRITOL AS LIPID 
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FIGURE-8B     KORSMEYER PEPPAS MODEL RELEASE 
KINETICS OF SLN USING GLYCERYL MONOSTEARATE AS 
LIPID 
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FIGURE-8C     KORSMEYER PEPPAS MODEL RELEASE 
KINETICS OF SLN USING GLYCERYL MONOOLEATE AS 
LIPID 
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FIGURE-8D     KORSMEYER PEPPAS MODEL RELEASE 
KINETICS OF SLN USING STEARIC ACID AS LIPID 
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FIGURE-8E     KORSMEYER PEPPAS MODEL RELEASE 
KINETICS OF SLN USING PALMITIC ACID AS LIPID 
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FIGURE-9A     HIXSON CROWELL MODEL KINETIC RELEASE 
OF SLN USING COMPRITOL AS LIPID 
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FIGURE-9B     HIXSON CROWELL MODEL KINETIC RELEASE 
OF SLN USING GLYCERYL MONOSTEARATE AS LIPID 
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FIGURE-9C     HIXSON CROWELL MODEL KINETIC RELEASE 
OF SLN USING GLYCERYL MONOOLEATE AS LIPID 
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FIGURE-9D      HIXSON CROWELL MODEL KINETIC 
RELEASE OF SLN USING STEARIC ACID AS LIPID 
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FIGURE-9E     HIXSON CROWELL MODEL KINETIC RELEASE 
OF SLN USING PALMITIC ACID AS LIPID 
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FIGURE-10A     PARTICLE SIZE DISTRIBUTION CURVE OF 
SLN6 (COMPRITOL ATO 888-10%) 
 
 
FIGURE-10B     PARTICLE SIZE DISTRIBUTION CURVE OF 
SLN12 (GLYCERYL MONOSTEARATE-10%)
 
 
FIGURE-10C     PARTICLE SIZE DISTRIBUTION CURVE OF 
SLN18 (GLYCERYL MONOOLEATE-10%)
 
 
FIGURE-10D     PARTICLE SIZE DISTRIBUTION CURVE OF 
SLN24 (STEARIC ACID-10%)
 
 
FIGURE-10E     PARTICLE SIZE DISTRIBUTION CURVE OF 
SLN30 (PALMITIC ACID-10%) 
 
 
FIGURE-11A     ZETA POTENTIAL CURVE OF SLN6              
(COMPRITOL ATO 888-10%) 
 
 
FIGURE-11B     ZETA POTENTIAL CURVE OF SLN12               
(GLYCERYL MONOSTEARATE-10%) 
 
 
FIGURE-11C     ZETA POTENTIAL CURVE OF SLN18               
(GLYCERYL MONOOLEATE-10%) 
 
 
FIGURE-11D     ZETA POTENTIAL CURVE OF SLN24                   
(STEARIC ACID-10%) 
 
 
FIGURE-11E     ZETA POTENTIAL CURVE OF SLN30                 
(PALMITIC ACID-10%) 
 
 
FIGURE-12     SOLUBILITY STUDIES 
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FIGURE-13     ANGLE OF REPOSE 
 
 
FIGURE-14     BULK DENSITY 
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FIGURE-15     TAPPED DENSITY 
 
 
FIGURE-16     MUCOADHESIVE STRENGTH 
 
 
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
0.67
0.68
F1 F2 F3
TA
P
P
ED
 D
EN
SI
TY
 g
/m
l 
FORMULATIONS 
33
33.5
34
34.5
35
35.5
36
36.5
37
37.5
38
F1 F2 F3
M
U
C
O
A
D
H
ES
IV
E 
ST
R
EN
G
TH
 (
gm
) 
 
FORMULATIONS 
FIGURE-17     SWELLING INDEX 
 
 
 
FIGURE-18     INVITRO DRUG RELEASE OF MUCOADHESIVE 
TABLETS 
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FIGURE-19A     ZERO ORDER INVITRO RELEASE KINETICS 
 
FIGURE-19B     FIRST ORDER INVITRO RELEASE KINETICS 
 
FIGURE-19C     HIXON CROWELL INVITRO RELEASE 
KINETICS 
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FIGURE-19D    KORSMEYER PEPPAS INVITRO RELEASE 
KINETICS 
 
 
 
FIGURE-19E     HIGUCHI INVITRO RELEASE KINETICS 
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FIGURE-20     EXVIVO DRUG PERMEATION STUDIES 
THROUGH RAT STOMACH 
 
 
FIGURE-21A     SEM IMAGE OF SLN6 (COMPRITOL) 
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FIGURE-21B     SEM IMAGE OF SLN12 (GMS) 
 
FIGURE-21C     SEM IMAGE OF SLN18 (GMO) 
 
 
 
FIGURE-22A     X-RAY DIFFRACTION OF CEFUROXIME 
AXETIL 
 
FIGURE-22B     X-RAY DIFFRACTION OF LYOPHILIZED SLN6 
 
FIGURE-22C     X-RAY DIFFRACTION OF LYOPHILIZED 
SLN12 
 
FIGURE-22D     X-RAY DIFFRACTION OF LYOPHILIZED 
SLN18 
 
FIGURE-23A INVIVO STUDIES IN RABBIT STOMACH 
(CONTROL) 
 
 
FIGURE-23B      INVIVO STUDIES IN RABBIT STOMACH          
(0 HOUR) 
 
 
FIGURE-23C      INVIVO STUDIES IN RABBIT STOMACH          
(2 HOUR) 
 
FIGURE-23D      INVIVO STUDIES IN RABBIT STOMACH          
(4 HOUR) 
 
 
FIGURE-23E      INVIVO STUDIES IN RABBIT STOMACH          
(6 HOUR) 
 
 
FIGURE-23F      INVIVO STUDIES IN RABBIT STOMACH          
(8 HOUR) 
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CHAPTER - 10 
SUMMARY & CONCLUSION 
 The main purpose of this investigation was to develop mucoadhesive tablets of 
cefuroxime axetil loaded in solid lipid nanoparticles (SLNs) to improve 
cefuroxime axetil bioavilability. 
 From the FT-IR studies there were no interactions between the drug and 
excipients was seen. 
 SLNs were prepared by hot homogenization followed by ultrasonication using 
various lipids such as glyceryl behenate (compritol ATO 888), glyceryl 
monostearate, glyceryl monooleate, stearic acid & palmitic acid and 
surfactants pluoric F68 & soyalecithin. 
 Entrapment efficiency of the formulations increase with increase in lipid 
percentage with an optimum surfactant concentration. 
 The particle size of formulations with best entrapment was found out in the 
range of 104.3nm-512.6nm. 
 The polydispersity index was within 0.55 indicating an uniform size 
distribution. 
 The zeta potential of the formulation with best entrapment was in the range of 
-9.42—22.9mV. 
 The invitro drug release showed a biphasic release pattern ie., burst release 
followed by sustained effect in 12hours. 
 The release kinetics showed that the formulations were diffusion controlled. 
Korsmeyer peppas n values were more than 0.4 indicating, non fickian 
diffusion. 
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 The best formulation was selected according to entrapment, particle size & 
invitro drug release. 
 Solubility studies were done for the best formulation which showed a higher 
solubility for formulation with lowest particle size. 
 The selected formulations were lyophilized. 
 The x-ray diffraction studies showed an amorphous form of the drug. 
 SEM images showed that the formulation were spherical in shape and had an 
almoat smooth appearance. 
 The selected lyophilized formulations were then compressed into 
mucoadhesive tablets using suitable polymers (HPMC K15M & carbopol 934) 
by direct compression method. 
 The mucoadhesive approach was applied to target the drug to the upper part of 
gastro intestinal tract, since cefuroxime axetil absorption happens only at 
1.2pH. 
 The precompression studies showed good flowability of the powder blend. 
 The post compression evaluation studies were evaluated for the fabricated 
tablets and were within the limits. 
 Since hydrophilic polymers were used good swelling of the tablets were 
observed. 
 Since carbopol is a very good mucoadhesive polymer optimum mucoadhesion 
was observed during mucoadhesive strength studies. 
 The invitro drug release of the formulations showed an optimum drug release 
due to the presence of swellable hydrophilic polymers for 12hours in a 
controlled manner. 
CHAPTER – X     SUMMARY & CONCLUSION 
MUCOADHESIVE TABLETS OF SLN LOADED WITH DRUG Page 97 
 
 The invitro release kinetics showed that the formulation follow diffusion 
controlled drug release. The n value of formulations in korsmeyer peppas were 
less than 0.4 indicating fickian diffusion. 
 The exvivo studies showed an increase in drug permeation in formulation with 
lyophilized SLN loaded with drug due to the nano size of the SLN formulation 
in it. 
 From the invivo x-ray studies done in rabbit, it was shown that the 
mucoadhesive formulation was retained for 8hours. 
  From these studies it was concluded that mucoadhesive tablets of 
cefuroxime axetil loaded in SLNs prove to be a successful gastroretentive oral 
delivery of the poor bioavailable drug. Since the drug was incorporated into lipids 
and the particle size was reduced to nano, enhanced permeation was observed and 
solubility was also increased due to increased surface area. The presence of muco 
adhesive polymer results in adhesion of tablet to the upper gastric mucosa 
resulting in targeted drug delivery. The overall results indicate the success of 
developing mucoadhesive tablets of cefuroxime axetil loaded in SLNs for stomach 
targeting.  
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